2. Search Result

Search Result

Targets Recommended: PI4K MAP4K Target Protein Ligand-Linker Conjugate Oct3/4 E3 Ligase Ligand-Linker Conjugate Ligand for Target Protein for PROTAC Ligand for E3 Ligase FXR Serotonin Transporter PD-1/PD-L1

Results for "4-1BB Ligand Inhibitors" in MCE Product Catalog:

540

Inhibitors & Agonists

15

Screening Libraries

4

Dye Reagents

2

Biochemical Assay Reagents

65

Peptides

3

Inhibitory Antibodies

26

Natural
Products

18

Recombinant Proteins

Cat. No. Product Name Target Research Areas
  • HY-133045
    VHL Ligand 8

    		Ligand for E3 Ligase Cancer
    VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC50 values of 0.2-1 nM.
  • HY-126534
    CDK ligand for PROTAC

    		CDK Ligand for Target Protein for PROTAC Cancer
    CDK ligand for PROTAC is a CDK inhibitor with antitumor activity. CDK ligand for PROTAC and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.
  • HY-126534A
    CDK ligand for PROTAC hydrochloride

    		CDK Ligand for Target Protein for PROTAC Cancer
    CDK ligand for PROTAC hydrochloride is a CDK inhibitor with antitumor activity. CDK ligand for PROTAC hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.
  • HY-126456
    (S,R,S)-AHPC-propargyl

    VH032-propargyl; VHL Ligand 7

    		 Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC-propargyl (VH032-propargyl) is a VHL ligand which is used in “click reaction” for PROTACs.
  • HY-133073
    CCR7 Ligand 1

    CCR7-Cmp2105

    		 CCR Ligand for Target Protein for PROTAC Cancer
    CCR7 Ligand 1 (CCR7-Cmp2105) is an allosteric Ligand and antagonist for human CC chemokine receptor 7 (CCR7) with a Kd of 3 nM. CCR7 Ligand 1, thiadiazole-dioxide ligan, suppresses arrestin binding in response to activation by CCL19 with an IC50 of 7.3 μM.
  • HY-P1840A
    Galanin Receptor Ligand M35 TFA

    		Neuropeptide Y Receptor Endocrinology Neurological Disease
    Galanin Receptor Ligand M35 TFA is a high-affinity ligand and antagonist of galanin receptor (Kd=0.1 nM). Galanin Receptor Ligand M35 TFA exerts a Ki values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.
  • HY-P1840
    Galanin Receptor Ligand M35

    		Neuropeptide Y Receptor Neurological Disease Endocrinology
    Galanin Receptor Ligand M35 is a high-affinity ligand and antagonist of galanin receptor (Kd=0.1 nM). Galanin Receptor Ligand M35 exerts a Ki values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.
  • HY-133046
    VHL Ligand-Linker Conjugates 17

    		E3 Ligase Ligand-Linker Conjugate Cancer
    VHL Ligand-Linker Conjugates 17 incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VHL Ligand-Linker Conjugates 17 can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020). ARD-266 is a highly potent androgen receptor (AR) PROTAC degrader.
  • HY-128808
    cIAP1 ligand 1

    E3 ligase Ligand 12

    		 Ligand for E3 Ligase Cancer
    cIAP1 ligand 1 is the LCL161 derivative based IAP ligand. cIAP1 ligand 1 can be connected to the ABL ligand for protein by a linker to form SNIPER.
  • HY-128809
    cIAP1 ligand 2

    E3 ligase Ligand 11

    		 Ligand for E3 Ligase Cancer
    cIAP1 ligand 2 is the LCL161 derivative based IAP ligand. cIAP1 ligand 2 can be connected to the ABL ligand for protein by a linker to form SNIPER.
  • HY-103597
    Thalidomide-O-COOH

    Cereblon Ligand 3; E3 ligase Ligand 3

    		 Ligand for E3 Ligase Others
    Thalidomide-O-COOH (Cereblon ligand 3) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-COOH (Cereblon ligand 3) can be connected to the ligand for protein by a linker to form PROTACs.
  • HY-103596
    Thalidomide-4-OH

    Cereblon Ligand 2; E3 ligase Ligand 2

    		 Ligand for E3 Ligase Cancer
    Thalidomide-4-OH (Cereblon ligand 2) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-4-OH (Cereblon ligand 2) can be connected to the ligand for protein by a linker to form PROTACs.
  • HY-128837
    Nutlin carboxylic acid

    MDM2 Ligand 1; E3 ligase Ligand 16

    		 Ligand for E3 Ligase Cancer
    Nutlin carboxylic acid (MDM2 ligand 1) is the Nutlin 3-based MDM2 ligand. Nutlin carboxylic acid (MDM2 ligand 1) can be connected to the ligand for protein by a linker to form PROTACs.
  • HY-114399
    STING ligand-1

    		STING Inflammation/Immunology
    STING ligand-1 is a lead STING ligand with an IC50 of 68 nM for HAQ STING.
  • HY-128807
    E3 ligase Ligand 10

    		Ligand for E3 Ligase Cancer
    E3 ligase Ligand 10 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 10 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.
  • HY-129653
    E3 ligase Ligand 18

    		Ligand for E3 Ligase Cancer
    E3 ligase Ligand 18 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 18 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.
  • HY-128811
    E3 ligase Ligand 14

    		Ligand for E3 Ligase Cancer
    E3 ligase Ligand 14 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 14 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.
  • HY-43961
    E3 ligase Ligand 8

    		Ligand for E3 Ligase Cancer
    E3 ligase Ligand 8 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 8 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.
  • HY-128810
    E3 ligase Ligand 13

    		Ligand for E3 Ligase Cancer
    E3 ligase Ligand 13 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 13 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.
  • HY-128806
    E3 ligase Ligand 9

    		Ligand for E3 Ligase Cancer
    E3 ligase Ligand 9 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 9 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.
  • HY-41547
    Thalidomide 4-fluoride

    Cereblon Ligand 4; E3 ligase Ligand 4

    		 Ligand for E3 Ligase Cancer
    Thalidomide 4-fluoride (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1 (HY-129966).
  • HY-U00439
    Protein kinase inhibitors 1

    		DYRK Cancer
    Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.
  • HY-130245
    PCSK9 ligand 1

    		Ser/Thr Protease Metabolic Disease
    PCSK9 ligand 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a Ki of 107 nM. PCSK9 ligand 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor.
  • HY-125905
    VH032-cyclopropane-F

    VHL Ligand 3; E3 ligase Ligand 19

    		 Ligand for E3 Ligase Cancer
    VH032-cyclopropane-F is the VH032-based VHL ligand. VH032-cyclopropane-F can be connected to the ligand for protein (e.g., SMARCA BD ligand) by a linker to form PROTACs (e.g., PROTAC 1). PROTAC 1 is a partial degrader of SMARCA2 and SMARCA4。
  • HY-111823
    VH032 thiol

    VHL Ligand 6

    		 Ligand for E3 Ligase Cancer
    VH032 thiol (VHL ligand 6) is a VHL ligand, which binds to pan-BET inhibitor JQ1 via a linker to form PROTAC.
  • HY-101626
    Sigma-LIGAND-1

    		Sigma Receptor Neurological Disease
    Sigma-LIGAND-1 is a selective sigma receptor ligand, has receptor IC50s of 16 nM at the DTG site, 19 nM at the PPP site, and a Ki of 4000 nM at the dopamine D2 receptor.
  • HY-129967
    PROTAC IRAK4 ligand-1

    		Ligand for Target Protein for PROTAC Cancer
    PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4 (IRAK4). PROTAC IRAK4 ligand-1 can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966).
  • HY-U00126
    5HT6-ligand-1

    		5-HT Receptor Neurological Disease
    5HT6-ligand-1 is a potent 5-HT6 receptor ligand with a Ki of 1.43 nM.
  • HY-128836
    (4R,5S)-Nutlin carboxylic acid

    MDM2 Ligand 2; E3 ligase Ligand 15

    		 Ligand for E3 Ligase Cancer
    (4R,5S)-Nutlin carboxylic acid (MDM2 ligand 2) is the Nutlin 3-based MDM2 ligand. (4R,5S)-Nutlin carboxylic acid can be connected to the ligand for protein by a linker to form PROTACs.
  • HY-126351
    PROTAC ERRα ligand 2

    		Estrogen Receptor/ERR Cancer
    PROTAC ERRα ligand 2 is an estrogen-related receptor α (ERRα) inverse agonist with an IC50 of 5.67 nM. PROTAC ERRα ligand 2 (IC50=5.67 nM) displays a ~11-fold improved potency than XCT790 (IC50=61.3 nM).
  • HY-129939
    PROTAC BRD4 ligand-1

    		Epigenetic Reader Domain Ligand for Target Protein for PROTAC Cancer
    PROTAC BRD4 ligand-1 is a potent BET inhibitor and a ligand for target BRD4 protein for PROTACT GNE-987 (HY-129937A).
  • HY-111845
    Estrone-N-O-C1-amido

    ERα Ligand 1

    		 Estrogen Receptor/ERR Ligand for Target Protein for PROTAC Cancer
    Estrone-N-O-C1-amido (ERα ligand 1) is an Estrone-based estrogen ligand, which targets estrogen receptor α (ERα). Estrone-N-O-C1-amido (ERα ligand 1) binds to cIAP1 ligand Bestatin via a linker to form SNIPER.
  • HY-111839
    ATRA-hydroxyimino

    CRABP-II Ligand 1

    		 Ligand for Target Protein for PROTAC Cancer
    ATRA-hydroxyimino (CRABP-II ligand 1), the Retinoic acid (ATRA)-based moiety, binds to cIAP1 ligand (Bestatin) via a linker to form SNIPER to degrade CRABP-II in IMR-32 cells.
  • HY-130297
    PROTAC BCR-ABL1 ligand 1

    		Bcr-Abl Cancer
    PROTAC BCR-ABL1 ligand 1, compound GMB-475, is the ligand of PROTAC that allosterically targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel-Lindau, resulting in ubiquitination and subsequent degradation of BCR-ABL1.
  • HY-130296
    Palbociclib-propargyl

    PROTAC CDK6 Ligand 1

    		 Ligand for Target Protein for PROTAC Cancer
    Palbociclib-propargyl is a ligand for target protein CDK6 for PROTAC, and binds to CRBN ligand via a PEG linker to make a PROTAC CP-10. CP-10 shows a DC50 of 2.1 nM for CDK6.
  • HY-111843
    Ch55-O-C3-NH2

    RAR Ligand 1

    		 RAR/RXR Ligand for Target Protein for PROTAC Autophagy Cancer
    Ch55-O-C3-NH2 (RAR ligand 1) is a Ch 55-based ligand, which targets RAR. Ch55-O-C3-NH2 (RAR ligand 1) binds to cIAP1 ligand Bestatin via a linker to form SNIPER.
  • HY-U00425
    PROTAC ERRα ligand 1

    		Estrogen Receptor/ERR Cancer
    PROTAC ERRα ligand 1 is an estrogen-related receptor α (ERRα) antagonist with IC50s of 0.04 and 2.8 μM for ERRα and ERRγ, respectively.
  • HY-136306
    Metallo β-lactamase ligand 1

    		Bacterial Infection
    Metallo-beta-lactamase ligand 1 is a class B β-lactamase inhibitor with antibacterial activity extracted from patent WO2019221122A1, compound A.
  • HY-130270
    AhR Ligand-Linker Conjugates 1

    E3 Ligase Ligand-Linker Conjugates 57

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    AhR Ligand-Linker Conjugates 1 (E3 Ligase Ligand-Linker Conjugates 57) incorporates an IAP ligand for the E3 ubiquitin ligase, and a SNIPER linker. AhR Ligand-Linker Conjugates 1 can be used to design SNIPER.
  • HY-125906
    VHL Ligand-Linker Conjugates 15

    E3 Ligase Ligand-Linker Conjugates 56

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    VHL Ligand-Linker Conjugates 15 incorporates an VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VHL Ligand-Linker Conjugates 15 can be used to design PROTACs.
  • HY-44012
    SMARCA-BD ligand 1 for Protac

    		Ligand for Target Protein for PROTAC Cancer
    SMARCA-BD ligand 1 for Protac is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
  • HY-44012A
    SMARCA-BD ligand 1 for Protac dihydrochloride

    		Ligand for Target Protein for PROTAC Cancer
    SMARCA-BD ligand 1 for Protac dihydrochloride is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
  • HY-128822
    cIAP1 Ligand-Linker Conjugates 13

    E3 ligase Ligand-Linker Conjugates 43

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 13 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 13 can be used to design SNIPERs.
  • HY-128815
    cIAP1 Ligand-Linker Conjugates 14

    E3 ligase Ligand-Linker Conjugates 36

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 14 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 14 can be used to design SNIPERs.
  • HY-128820
    cIAP1 Ligand-Linker Conjugates 1

    E3 ligase Ligand-Linker Conjugates 41

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 1 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 1 can be used to design SNIPERs.
  • HY-128819
    cIAP1 Ligand-Linker Conjugates 3

    E3 ligase Ligand-Linker Conjugates 40

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 3 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 3 can be used to design SNIPERs.
  • HY-128826
    cIAP1 Ligand-Linker Conjugates 10

    E3 ligase Ligand-Linker Conjugates 47

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 10 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 10 can be used to design SNIPERs.
  • HY-128813
    cIAP1 Ligand-Linker Conjugates 15

    E3 ligase Ligand-Linker Conjugates 34

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 15 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 can be used to design SNIPERs.
  • HY-128824
    cIAP1 Ligand-Linker Conjugates 9

    E3 ligase Ligand-Linker Conjugates 45

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 9 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 9 can be used to design SNIPERs.
  • HY-128812
    cIAP1 Ligand-Linker Conjugates 11

    E3 ligase Ligand-Linker Conjugates 33

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 11 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 can be used to design SNIPERs.
  • HY-128817
    cIAP1 Ligand-Linker Conjugates 12

    E3 ligase Ligand-Linker Conjugates 38

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 12 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 12 can be used to design SNIPERs.
  • HY-128825
    cIAP1 Ligand-Linker Conjugates 8

    E3 ligase Ligand-Linker Conjugates 46

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 8 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 8 can be used to design SNIPERs.
  • HY-128823
    cIAP1 Ligand-Linker Conjugates 7

    E3 ligase Ligand-Linker Conjugates 44

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 7 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 7 can be used to design SNIPERs.
  • HY-128818
    cIAP1 Ligand-Linker Conjugates 5

    E3 ligase Ligand-Linker Conjugates 39

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 5 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 5 can be used to design SNIPERs.
  • HY-128821
    cIAP1 Ligand-Linker Conjugates 4

    E3 ligase Ligand-Linker Conjugates 42

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 4 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 4 can be used to design SNIPERs.
  • HY-128816
    cIAP1 Ligand-Linker Conjugates 2

    E3 ligase Ligand-Linker Conjugates 37

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 2 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 2 can be used to design SNIPERs.
  • HY-P1887
    p5 Ligand for Dnak and DnaJ

    		HSP Infection
    p5 Ligand for Dnak and DnaJ is a nonapeptide, which corresponds to the main binding site for the 23-residue part of the presequence of mitochondrial aspartate aminotransferase. p5 Ligand for Dnak and DnaJ is a high-affinity ligand for DnaK and DnaJ.
  • HY-KT001
    E3 Ligase Ligand-Linker Conjugate Kit

    		E3 Ligase Ligand-Linker Conjugate Cancer
    E3 Ligase Ligand-Linker Conjugate Kit is a series of synthesized compounds that incorporate an E3 ligase ligand and a linker used in PROTAC technology.
  • HY-44148
    FAK ligand-Linker Conjugate 1

    		Target Protein Ligand-Linker Conjugate Cancer
    FAK ligand-Linker Conjugate 1 incorporates a ligand for FAK, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). FAK ligand-Linker Conjugate 1 can be extensively used for PROTAC-mediated protein degradation.
  • HY-42424A
    (S,R,S)-AHPC-Me dihydrochloride

    VHL Ligand 2 dihydrochloride; E3 ligase Ligand 1 dihydrochloride

    		 Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC-Me dihydrochloride (VHL ligand 2 dihydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me dihydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC50 <1 nM.
  • HY-128813A
    cIAP1 Ligand-Linker Conjugates 15 hydrochloride

    E3 ligase Ligand-Linker Conjugates 34 hydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 15 hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 hydrochloride can be used to design SNIPERs.
  • HY-128816A
    cIAP1 Ligand-Linker Conjugates 2 Hydrochloride

    E3 ligase Ligand-Linker Conjugates 37 Hydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 2 Hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 2 Hydrochloride can be used to design SNIPERs.
  • HY-128812A
    cIAP1 Ligand-Linker Conjugates 11 Hydrochloride

    E3 ligase Ligand-Linker Conjugates 33 Hydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 11 Hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 Hydrochloride can be used to design SNIPERs.
  • HY-128814
    cIAP1 Ligand-Linker Conjugates 6 hydrochloride

    E3 ligase Ligand-Linker Conjugates 35 hydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    cIAP1 Ligand-Linker Conjugates 6 hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 6 hydrochloride can be used to design SNIPERs.
  • HY-12512
    cGAMP

    Cyclic GMP-AMP; 3',3'-cGAMP

    		 STING Inflammation/Immunology
    cGAMP (Cyclic GMP-AMP; 3',3'-cGAMP) is an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA; STING ligand.
  • HY-42424
    (S,R,S)-AHPC-Me hydrochloride

    VHL Ligand 2 hydrochloride; E3 ligase Ligand 1

    		 Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me hydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC50 <1 nM.
  • HY-130499
    ERRα Ligand-Linker Conjugates 1

    		Target Protein Ligand-Linker Conjugate Cancer
    ERRα Ligand-Linker Conjugates 1 incorporates a ligand for estrogen-related receptor alpha (ERRα), and a PROTAC linker, which recruit E3 ligases MDM2. ERRα Ligand-Linker Conjugates 1 can be used in the synthesis of a series of PROTACs, such as PROTAC ERRalpha Degrader-1 (HY-128838). PROTAC ERRalpha Degrader-1 is an ERRα degrader.
  • HY-129608
    Lenalidomide-acetylene-C5-COOH

    Cereblon Ligand-linker Conjugate

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Lenalidomide-acetylene-C5-COOH (compound 43; Cereblon ligand-linker Conjugate) is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-acetylene-C5-COOH can be connected to the ligand for protein by a linker to form PROTAC.
  • HY-133189
    Bis-propargyl-PEG9

    		PROTAC Linker Endocrinology
    Bis-propargyl-PEG9 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG9 can be used to synthesize the bivalent estrogen receptor ligands.
  • HY-130295
    Pomalidomide-PEG2-Tos

    Cereblon Ligand-Linker Conjugates 16; E3 ligase Ligand-Linker Conjugates 52

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-PEG2-Tos is an E3 ligase ligand-linker conjugates, composed of a cereblon ligand and two-unit PEG linker.
  • HY-112078
    (S,R,S)-AHPC-Me

    VHL Ligand 2; E3 ligase Ligand 1A

    		 Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC50 <1 nM.
  • HY-W007648
    Methyl 3-aminopropanoate hydrochloride

    β-Alanine methyl ester hydrochloride

    		 Others Others
    Methyl 3-aminopropanoate hydrochloride is prepared by esterification of Β-Alanine (I). Methyl 3-aminopropanoate hydrochloride can be used in the synthesis of bidentate pyridine-acid ligand.
  • HY-107439
    Thalidomide-O-amido-C8-NH2

    Cereblon Ligand-Linker Conjugates 2; E3 Ligase Ligand-Linker Conjugates 20

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.
  • HY-107438
    Thalidomide-O-amido-C4-NH2

    Cereblon Ligand-Linker Conjugates 6; E3 Ligase Ligand-Linker Conjugates 19

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.
  • HY-111824
    VH032-thiol-C6-NH2

    VHL Ligand-Linker Conjugates 14; E3 ligase Ligand-Linker Conjugates 29

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    VH032-thiol-C6-NH2 (VHL Ligand-Linker Conjugates 14) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.
  • HY-W087383
    Thalidomide 5-fluoride

    		Ligand for E3 Ligase Cancer
    Thalidomide 5-fluoride is Thalidomide-based cereblon ligand that incorporates to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1.
  • HY-N0927
    (-)-Isocorypalmine

    Tetrahydrocolumbamine; (S)-Tetrahydrocolumbamine

    		 Dopamine Receptor Others
    (-)-Isocorypalmine (Tetrahydrocolumbamine), isolated from the crude base fraction of Corydalis chaerophylla, is a dopamine receptor ligand. Recombinant CYP719A21 displays strict substrate specificity and high affinity (Km=4.63 ± 0.71 μM) for (-)-Isocorypalmine.
  • HY-130979
    EED226-COOH

    		Ligand for Target Protein for PROTAC Cancer
    EED226-COOH is an EED226-derived ligand for target protein EED ligand for PROTAC, binds to a ligand for VHL via linker to form UNC6852 (HY-130708) to degrade PRC2.
  • HY-129776
    K-Ras ligand-Linker Conjugate 2

    		Target Protein Ligand-Linker Conjugate Cancer
    K-Ras ligand-Linker Conjugate 2 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 2 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.
  • HY-129775
    K-Ras ligand-Linker Conjugate 1

    		Target Protein Ligand-Linker Conjugate Cancer
    K-Ras ligand-Linker Conjugate 1 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 1 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.
  • HY-103612
    Thalidomide-O-amido-C3-COOH

    Cereblon Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 15

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-130822
    K-Ras ligand-Linker Conjugate 4

    		Target Protein Ligand-Linker Conjugate Cancer
    K-Ras ligand-Linker Conjugate 4 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 4 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.
  • HY-130823
    K-Ras ligand-Linker Conjugate 5

    		Target Protein Ligand-Linker Conjugate Cancer
    K-Ras ligand-Linker Conjugate 5 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 5 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.
  • HY-130991
    K-Ras ligand-Linker Conjugate 6

    		Target Protein Ligand-Linker Conjugate Cancer
    K-Ras ligand-Linker Conjugate 6 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 6 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.
  • HY-130707
    K-Ras ligand-Linker Conjugate 3

    		Target Protein Ligand-Linker Conjugate Cancer
    K-Ras ligand-Linker Conjugate 3 (Compound 001371) incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 3 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.
  • HY-21930
    Pomalidomide-PEG4-C-COOH

    Cereblon Ligand -Linker Conjugates 1; E3 Ligase Ligand-Linker Conjugates 1

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-PEG4-C-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.
  • HY-133486
    GABAA receptor agent 1

    		GABA Receptor Neurological Disease
    GABAA receptor agent 1 is a high affinity ligand for GABAA receptor, with potent anticonvulsant activity.
  • HY-128941
    CCK2R Ligand-Linker Conjugates 1

    		Drug-Linker Conjugates for ADC Cancer
    CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker.
  • HY-103614
    Thalidomide-O-amido-C8-NH2 (TFA)

    Cereblon Ligand -Linker Conjugates 2 (TFA); E3 Ligase Ligand-Linker Conjugates 20 (TFA)

    		 E3 Ligase Ligand-Linker Conjugate Others
    Thalidomide-O-amido-C8-NH2 TFA (Cereblon Ligand -Linker Conjugates 2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-103613
    Thalidomide-O-amido-C4-NH2 (TFA)

    Cereblon Ligand-Linker Conjugates 6 (TFA); E3 ligase Ligand-Linker Conjugates 19 (TFA)

    		 E3 Ligase Ligand-Linker Conjugate Others
    Thalidomide-O-amido-C4-NH2 TFA (Cereblon Ligand-Linker Conjugates 6 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-115446A
    Lenalidomide-C4-NH2 hydrochloride

    Cereblon Ligand 1 hydrochloride; E3 ligase Ligand-Linker Conjugates 32 hydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Lenalidomide-C4-NH2 hydrochloride is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C4-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC (Compound 24), which has IC50s of 0.98 nM and 13.7 nM in inhibition of RS4;11 and MOLM-13 acute leukemia cell lines growth, respectively.
  • HY-130716
    Thalidomide-NH-C10-COOH

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-NH-C10-COOH (compound 6b) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based von Hippel-Lindau (VHL) ligand and a linker used in PROTAC technology.
  • HY-130521
    Pomalidomide-amido-PEG3-C2-NH2

    Cereblon Ligand-Linker Conjugates 22; E3 ligase Ligand-Linker Conjugates 55

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 22) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-112618A
    Thalidomide-O-amido-C6-NH2 TFA

    Cereblon Ligand-Linker Conjugates 11 TFA; E3 Ligase Ligand-Linker Conjugates 25 TFA

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.
  • HY-103615
    Thalidomide-O-amido-C4-N3

    Cereblon Ligand-Linker Conjugates 4; E3 ligase Ligand-Linker Conjugates 18

    		 E3 Ligase Ligand-Linker Conjugate Others
    Thalidomide-O-amido-C4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-107440
    Thalidomide-O-amido-PEG3-C2-NH2

    Cereblon Ligand-Linker Conjugates 3 ; E3 Ligase Ligand-Linker Conjugates 14

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-122725
    Lenalidomide-C5-NH2

    Cereblon Ligand-Linker Conjugates 19; E3 ligase Ligand-Linker Conjugates 31

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Lenalidomide-C5-NH2 is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs.
  • HY-41549
    Pomalidomide-PEG4-Ph-NH2

    Cereblon Ligand-Linker Conjugates 9; E3 Ligase Ligand-Linker Conjugates 2

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-PEG4-Ph-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.
  • HY-125845
    (S,R,S)-AHPC

    VH032-NH2; VHL Ligand 1

    		 Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC (VH032-NH2) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC50 of 1.11 μM in Ba/F3 cells.
  • HY-128846
    Pomalidomide-C2-NH2

    Cereblon Ligand-Linker Conjugates 15

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology.
  • HY-128716
    Pomalidomide-PEG3-C2-NH2

    Cereblon Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 30

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-112599
    Pomalidomide-PEG4-C2-NH2

    Cereblon Ligand-Linker Conjugates 8; E3 Ligase Ligand-Linker Conjugates 22

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.
  • HY-101763A
    (S,R,S)-AHPC hydrochloride

    VH032-NH2 hydrochloride; VHL Ligand 1 hydrochloride

    		 Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC hydrochloride is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC hydrochloride can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC50 of 1.11 μM in Ba/F3 cells.
  • HY-115560A
    Thalidomide-O-amido-C3-NH2 (TFA)

    Cereblon Ligand-Linker Conjugates 16 (TFA); E3 Ligase Ligand-Linker Conjugates 52 (TFA)

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-C3-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-109176
    Giredestrant

    GDC-9545

    		 Estrogen Receptor/ERR Cancer
    Giredestrant (GDC-9545), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity.
  • HY-125884
    Pomalidomide-amido-C4-amido-C6-NH-Boc

    Cereblon Ligand-Linker Conjugates 21; E3 Ligase Ligand-Linker Conjugates 54

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-amido-C4-amido-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-126458
    Thalidomide-O-PEG2-propargyl

    E3 ligase Ligand-Linker Conjugates 32

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-PEG2-propargyl (E3 ligase Ligand-Linker Conjugates 32) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.
  • HY-P1868
    α2β1 Integrin Ligand Peptide

    		Integrin Infection
    α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.
  • HY-136424
    GPI-1485

    GM1485

    		 Others Neurological Disease
    GPI-1485 (GM1485), a nonimmunosuppressive immunophilin ligand, promotes neurofunctional improvement and neural regeneration following stroke.
  • HY-128846A
    Pomalidomide-C2-NH2 hydrochloride

    Cereblon Ligand-Linker Conjugates 15 hydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-128839
    PROTAC ERRα Degrader-2

    		PROTAC Estrogen Receptor/ERR Cancer
    PROTAC ERRα Degrader-2 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-2 is an estrogen-related receptor alpha (ERRa) degrader.
  • HY-128716A
    Pomalidomide-PEG3-C2-NH2 TFA

    Cereblon Ligand-Linker Conjugates 5 TFA; E3 ligase Ligand-Linker Conjugates 30 TFA

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-110402
    (S,R,S)-AHPC TFA

    VH032-NH2 TFA; VHL Ligand 1 TFA

    		 Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC TFA (VH032-NH2 TFA) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC TFA can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC50 of 1.11 μM in Ba/F3 cells.
  • HY-P1868A
    α2β1 Integrin Ligand Peptide TFA

    		Integrin Others
    α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.
  • HY-125846
    (S,R,S)-AHPC-PEG1-OTs

    VH032-PEG1-OTs; VHL Ligand-Linker Conjugates 2; E3 ligase Ligand-Linker Conjugates 51

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG1-OTs is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.
  • HY-135903
    Giredestrant tartrate

    GDC-9545 tartrate

    		 Estrogen Receptor/ERR Cancer
    Giredestrant tartrate (GDC-9545 tartrate), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant tartrate potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Anti-tumor activity.
  • HY-112617A
    Thalidomide-O-amido-PEG2-C2-NH2 TFA

    Cereblon Ligand-Linker Conjugates 10 TFA; E3 Ligase Ligand-Linker Conjugates 24 TFA

    		 E3 Ligase Ligand-Linker Conjugate Cancer Inflammation/Immunology
    Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.
  • HY-103611
    Thalidomide-O-amido-PEG3-C2-NH2 (TFA)

    Cereblon Ligand-Linker Conjugates 3 (TFA); E3 ligase Ligand-Linker Conjugates 14 (TFA)

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-125883
    Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc

    Cereblon Ligand-Linker Conjugates 20; E3 Ligase Ligand-Linker Conjugates 53

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.
  • HY-122136
    S26131

    		Melatonin Receptor Neurological Disease
    S26131 (compound 5) is a potent and selective MT1 melatoninergic ligand, and the Ki values are 0.5 and 112 nM for MT1 and MT2, respectively. S26131 behaves as an MT1 and MT2 antagonist.
  • HY-128832
    Nutlin-C1-amido-PEG4-C2-N3

    MDM2 Ligand-Linker Conjugates 1; E3 ligase Ligand-Linker Conjugates 48

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Nutlin-C1-amido-PEG4-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Nutlin 3 based MDM2 ligand and 4-unit PEG linker used in PROTAC technology.
  • HY-103599
    (S,R,S)-AHPC-PEG2-N3

    VH032-PEG2-N3; VHL Ligand-Linker Conjugates 6; E3 ligase Ligand-Linker Conjugates 13

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology.
  • HY-103601
    (S,R,S)-AHPC-PEG4-N3

    VH032-PEG4-N3; VHL Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 4

    		 E3 Ligase Ligand-Linker Conjugate Others
    (S,R,S)-AHPC-PEG4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.
  • HY-103600
    (S,R,S)-AHPC-PEG1-N3

    VH032-PEG1-N3; VHL Ligand-Linker Conjugates 9; E3 ligase Ligand-Linker Conjugates 3

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.
  • HY-103598
    (S,R,S)-AHPC-PEG3-N3

    VH032-PEG3-N3; VHL Ligand-Linker Conjugates 8; E3 ligase Ligand-Linker Conjugates 12

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG3-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-114176
    (S,R,S)-AHPC-C4-NH2 hydrochloride

    VH032-C4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 13; E3 ligase Ligand-Linker Conjugates 28

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.
  • HY-103602A
    (S,R,S)-AHPC-PEG3-NH2

    VH032-PEG3-NH2; VHL Ligand-Linker Conjugates 1; E3 ligase Ligand-Linker Conjugates 5 Free Base

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-103604A
    (S,R,S)-AHPC-PEG4-NH2

    VH032-PEG4-NH2; VHL Ligand-Linker Conjugates 4 ; E3 ligase Ligand-Linker Conjugates 7 Free Base

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.
  • HY-128848
    Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH

    Cereblon Ligand-Linker Conjugates 14; E3 ligase Ligand-Linker Conjugates 49

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-130271
    (S,R,S)-AHPC-PEG5-COOH

    VH032-PEG5-COOH; VHL Ligand-Linker Conjugates 16; E3 Ligase Ligand-Linker Conjugates 58

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG5-COOH (VH032-PEG5-COOH) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 5-unit PEG linker used in PROTAC technology.
  • HY-103604
    (S,R,S)-AHPC-PEG4-NH2 hydrochloride

    VH032-PEG4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 4 hydrochloride; E3 ligase Ligand-Linker Conjugates 7

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.
  • HY-103602
    (S,R,S)-AHPC-PEG3-NH2 hydrochloride

    VH032-PEG3-NH2 hydrochloride; VHL Ligand-Linker Conjugates 1 hydrochloride; E3 ligase Ligand-Linker Conjugates 5

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-P1483
    Urotensin II, mouse

    		Urotensin Receptor Neurological Disease Cardiovascular Disease
    Urotensin II, mouse is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse is a potent vasoconstrictor. Urotensin II, mouse plays a physiological role in the central nervous system.
  • HY-P1483B
    Urotensin II, mouse acetate

    		Urotensin Receptor Neurological Disease Cardiovascular Disease
    Urotensin II, mouse acetate is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse acetate is a potent vasoconstrictor. Urotensin II, mouse acetate plays a physiological role in the central nervous system.
  • HY-130982
    Lenalidomide-PEG3-iodine

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Lenalidomide-PEG3-iodine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Lenalidomide based cereblon ligand and a 3-unit PEG linker. Lenalidomide-PEG3-iodine can be used in the synthesis of a series of PROTACs, such as SJF620 (HY-133137). SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM.
  • HY-130798
    (S,R,S)-AHPC-amido-C5-acid

    		E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-amido-C5-acid incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-amido-C5-acid can be used to design XY028-133 (HY-129180).
  • HY-112600A
    Thalidomide-O-amido-PEG1-(C1-​PEG)2-C2-NH2

    Cereblon Ligand-Linker Conjugates 12 TFA; E3 Ligase Ligand-Linker Conjugates 23 TFA

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-PEG1-(C1-​PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-130813
    BET-IN-6

    		Ligand for Target Protein for PROTAC Epigenetic Reader Domain Cancer
    BET-IN-6 is a potent and high affnity BRD2/BRD4 inhibitor. BET-IN-6 is the ligand for target protein BRD2/4, and is used for the systhesis of PROTAC BRD2/BRD4 degrader-1 (HY-130612).
  • HY-P1483A
    Urotensin II, mouse TFA

    		Urotensin Receptor Neurological Disease Cardiovascular Disease
    Urotensin II, mouse TFA is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse TFA is a potent vasoconstrictor. Urotensin II, mouse TFA plays a physiological role in the central nervous system.
  • HY-123109
    (S,R,S)-AHPC-Boc

    VH032-Boc

    		 Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC-Boc (VH032-Boc) is a ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Boc is used in PROTAC technology.
  • HY-131005
    Ehp inhibitor 2

    		Ephrin Receptor Cancer
    Ehp inhibitor 2 is a Eph family tyrosine kinase inhibitor.
  • HY-125843
    Pomalidomide-PEG1-C2-N3

    Cereblon Ligand-Linker Conjugates 13; E3 ligase Ligand-Linker Conjugates 50

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-PEG1-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology. Pomalidomide-PEG1-C2-N3 can be used to design a selective CDK6 PROTAC degrader CP-10. CP-10 induces the degradation of CDK6 with an DC50 of 2.1 nM.
  • HY-103603A
    (S,R,S)-AHPC-PEG2-NH2

    VH032-PEG2-NH2 ; VHL Ligand-Linker Conjugates 3 ; E3 ligase Ligand-Linker Conjugates 6 Free Base

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG2-NH2 (VH032-PEG2-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.
  • HY-103603
    (S,R,S)-AHPC-PEG2-NH2 hydrochloride

    VH032-PEG2-NH2 hydrochloride; VHL Ligand-Linker Conjugates 3 hydrochloride; E3 ligase Ligand-Linker Conjugates 6

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG2-NH2 hydrochloride (VH032-PEG2-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.
  • HY-101178
    L-689560

    		iGluR Neurological Disease
    L-689560 is a potent N-methyl-D-aspartate (NMDA) receptor antagonist at the GluN1 glycine binding site. L-689560 is widely used as a radiolabeled ligand in binding studies and used for study the roles of NMDA receptors in normal neurological processes as well as in diseases.
  • HY-136363
    MDR-652

    		TRP Channel Neurological Disease
    MDR-652 is a highly specific and efficacious transient receptor potential vanilloid 1 (TRPV1) ligand with agonist activity. The Kis are 11.4 and 23.8 nM for hTRPV1 and rTRPV1, respectively. The EC50s are 5.05 and 93 nM for hTRPV1 and rTRPV1, respectively. Potent topical analgesic activity.
  • HY-121879
    SHP836

    		Phosphatase Cancer
    SHP836 is a SHP2 allosteric inhibitor, with an IC50 of 12 μM for the full length SHP2.
  • HY-135236
    OXFBD04

    		Epigenetic Reader Domain Cancer
    OXFBD04 is a potent and selective BRD4 inhibitor with an IC50 of 166 nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity.
  • HY-131295
    PD0325901-O-C2-dioxolane

    		MEK Ligand for Target Protein for PROTAC Cancer
    PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader.
  • HY-P1318
    Ac-RYYRIK-NH2

    		Opioid Receptor Neurological Disease
    Ac-RYYRIK-NH2 is a potent and partial agonist on ORL1 transfected in CHO cells (Kd=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ 35S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain.
  • HY-P1318A
    Ac-RYYRIK-NH2 TFA

    		Opioid Receptor Neurological Disease
    Ac-RYYRIK-NH2 TFA is a potent and partial agonist on ORL1 transfected in CHO cells (Kd=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ 35S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain.
  • HY-19373
    RWJ-445167

    3DP-10017

    		 Thrombin Factor Xa Cardiovascular Disease
    RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.
  • HY-16787
    ICA-121431

    		Sodium Channel Cardiovascular Disease
    ICA-121431 is a nanomolar potent and broad-spectrum voltage-gated sodium channel (Nav) blocker, shows equipotent selectivity for human Nav1.1 and Nav1.3 subtypes with IC50 values of 13 nM and 23 nM, respectively. ICA-121431 shows less potent inhibition of Nav1.2 (IC50=240 nM) and 1,000 fold selectivity against Nav1.4, Nav1.6, and the TTX-resistant human Nav1.5 and Nav1.8 channels (IC50s >10 µM).
  • HY-U00439A
    Protein kinase inhibitors 1 hydrochloride

    (E)-5-((2-Oxo-6'-(piperazin-1-yl)-1,2-dihydro-[3,3'-bipyridin]-5-yl)methylene)thiazolidine-2,4-dione hydrochloride

    		 DYRK Cancer
    Protein kinase inhibitors 1 hydrochloride is a potent HIPK2 inhibitor, with IC50s of 136 and 74 nM for HIPK1 and HIPK2, and a Kd of 9.5 nM for HIPK2.
  • HY-103076
    EZ-482

    		Others Neurological Disease
    EZ-482, a novel ligand of apolipoprotein (apoE), binds to sites on apoE in the C-terminal domain with Kds of 5-10 μM for apoE3 and apoE4. EZ-482 binds to apoE4 by a unique N-terminal allosteric effect. EZ482 has the potential for Alzheimer’s diseas.
  • HY-103608
    (S,R,S)-AHPC-(C3-​PEG)​2-​C6-​Cl

    VHL Ligand-Linker Conjugates 11; E3 ligase Ligand-Linker Conjugates 11

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-(C3-​PEG)​2-​C6-​Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-(C3-​PEG)​2-​C6-​Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
  • HY-114091
    PF-00356231 hydrochloride

    		MMP Inflammation/Immunology
    PF-00356231 hydrochloride is a specific, non-peptidic, non-zinc chelating ligand and inhibitor of matrix metalloproteinase MMP-12 (IC50=1.4 μM). PF-00356231 hydrochloride binds to MMP-12 and forms PF-00356231/MMP-12 complex. PF-00356231 hydrochloride shows potency against MMP-13, MMP-8, MMP-9, MMP-3 with IC50s of 0.00065, 1.7, 0.98, 0.39 μM, respectively.
  • HY-W012037
    8-Hydroxyquinoline hemisulfate

    8-Quinolinol hemisulfate

    		 Bacterial Antibiotic Infection
    8-Hydroxyquinoline hemisulfate (8-Quinolinol hemisulfate) is a monoprotic bidentate chelating agent, exhibits antiseptic, disinfectant, and pesticide properties, functioning as a transcription inhibitor.
  • HY-103606
    (S,R,S)-AHPC-PEG6-C4-Cl

    VH032-PEG6-C4-Cl; VHL Ligand-Linker Conjugates 10; E3 ligase Ligand-Linker Conjugates 9

    		 PROTAC Cancer
    (S,R,S)-AHPC-PEG6-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker. (S,R,S)-AHPC-PEG6-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
  • HY-103607
    (S,R,S)-AHPC-PEG2-C4-Cl

    VH032-PEG2-C4-Cl; VHL Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 10

    		 PROTAC Cancer
    (S,R,S)-AHPC-PEG2-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-PEG2-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
  • HY-113962
    7α,25-Dihydroxycholesterol

    7α,25-OHC

    		 EBI2/GPR183 Endogenous Metabolite Inflammation/Immunology
    7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC50=140 pM; Kd=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells.
  • HY-135813
    LtaS-IN-1

    		Bacterial Infection
    LtaS-IN-1 (compound 1771) is a potent small-molecule inhibitor of Lipoteichoic acid (LTA) synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 alone inhibits Enterococcus.spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 combination with antibiotics abolishs multidrug-resistant E. faecium growth almost completely.
  • HY-125957
    A-3 hydrochloride

    		PKA Casein Kinase CaMK PKC Others
    A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (Ki=4.3 µM), casein kinase II (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM). A-3 hydrochloride also inhibits PKC and casein kinase I with Ki values of 47 µM and 80 µM, respectively.
  • HY-113534
    MV1

    		IAP Others
    MV1 is an antagonist of IAP (inhibitor of apoptosis protein), leads to protein knockdown of HaloTag-fused proteins when combined with HaloTag ligand.
  • HY-A0003B
    Lenalidomide hemihydrate

    CC-5013 hemihydrate

    		 Ligand for E3 Ligase Apoptosis Cancer
    Lenalidomide hemihydrate (CC-5013 hemihydrate) is a derivative of Thalidomide and an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
  • HY-A0003
    Lenalidomide

    CC-5013

    		 Ligand for E3 Ligase Apoptosis Cancer Inflammation/Immunology
    Lenalidomide (CC-5013) is a derivative of Thalidomide and an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
  • HY-A0003A
    Lenalidomide hydrochloride

    CC-5013 hydrochloride

    		 Ligand for E3 Ligase Cancer Inflammation/Immunology
    Lenalidomide hydrochloride (CC-5013 hydrochloride) is a derivative of Thalidomide and an orally active immunomodulator. Lenalidomide hydrochloride (CC-5013 hydrochloride) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hydrochloride (CC-5013 hydrochloride) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
  • HY-103605
    (S,R,S)-AHPC-C6-PEG3-C4-Cl

    VH032-C6-PEG3-C4-Cl; VHL Ligand-Linker Conjugates 12; E3 ligase Ligand-Linker Conjugates 8

    		 PROTAC Cancer
    (S,R,S)-AHPC-C6-PEG3-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker. (S,R,S)-AHPC-C6-PEG3-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
  • HY-130952
    Thalidomide-O-C8-COOH

    		Ligand for E3 Ligase Cancer
    Thalidomide-O-C8-COOH is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-C8-COOH (Cereblon ligand 3) can be connected to the ligand for protein by a linker to form PROTACs.
  • HY-17360
    Tiotropium Bromide

    BA679 BR

    		 mAChR Neurological Disease
    Tiotropium Bromide (BA679 BR) is a muscarinic acetylcholine receptor (mAChR) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel.
  • HY-136269
    A 410099.1, amine-Boc hydrochloride

    		E3 Ligase Ligand-Linker Conjugate
    A 410099.1, amine-Boc hydrochloride is a functionalized IAP ligand for PROTACs. that is incorporates with an amine functional handle for ready conjugation to a linker/target protein ligand.
  • HY-108652
    α,β-Methylene ATP trisodium

    		Others Inflammation/Immunology
    α,β-Methylene ATP trisodium, a phosphonic analog of ATP, is a P2X3 and P2X7 receptor ligand.
  • HY-N1427A
    Glycodeoxycholic acid monohydrate

    		Others Cancer
    Glycodeoxycholic acid monohydrate is a nuclear receptor ligand.
  • HY-104046
    Octaaminocryptand 1

    		Others Others
    Octaaminocryptand 1 is an aminocryptand ligand.
  • HY-111847
    Androstanolone acetate

    		Androgen Receptor Ligand for Target Protein for PROTAC Cancer
    Androstanolone acetate is an androgen ligand, which targets androgen receptor (AR). Androstanolone acetate binds to cIAP1 ligand Bestatin via a linker to form PROTACs.
  • HY-101918
    DS-1040 Tosylate

    		Others Cardiovascular Disease
    DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases.
  • HY-18728
    STF-31

    		GLUT Autophagy Cancer
    STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC50 of 1μM[1][2].
  • HY-113413
    Imidazoleacetic acid

    Imidazolyl-4-acetic acid

    		 Endogenous Metabolite Metabolic Disease
    Imidazoleacetic acid is an endogenous ligand that stimulates imidazole receptors.
  • HY-126457
    Thalidomide-propargyl

    		Ligand for E3 Ligase Cancer
    Thalidomide-propargyl is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-propargyl can be connected to the ligand for protein by a linker to form the IMiD containing PROTACs.
  • HY-136183
    (S,R,S)-AHPC-phenol-alkylC6-amine dihydrochloride

    VH032 phenol-alkylC6-amine dihydrochloride

    		 E3 Ligase Ligand-Linker Conjugate
    (S,R,S)-AHPC-phenol-alkylC6-amine (dihydrochloride) is a functionalized von-Hippel-Lindau (VHL) protein ligand for PROTAC. (S,R,S)-AHPC-phenol-alkylC6-amine incorporates an E3 ligase ligand plus an alkyl linker ready for conjugation to a target protein ligand.
  • HY-112797
    Ds-HAPP

    		Others Others
    Ds-HAPP is an anthrancenyl and dansyl fluorophore ligand.
  • HY-131185
    Pomalidomide-amido-C3-COOH

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-amido-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-130737
    Pomalidomide 4'-alkylC5-acid

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide 4'-alkylC5-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology.
  • HY-103634
    dFKBP-1

    		PROTAC FKBP Cancer
    dFKBP-1 is a potent and PROTAC-based FKBP12 degrader. dFKBP-1 incorporates the ligand SLF of FKBP12, the Thalidomide based cereblon ligand and a linker.
  • HY-136184
    (S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride

    VH032-phenol-C4-NH2 dihydrochloride

    		 E3 Ligase Ligand-Linker Conjugate
    (S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride is a functionalized von-Hippel-Lindau (VHL) protein ligand for PROTAC. (S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride incorporates an E3 ligase ligand plus an alkyl linker ready for conjugation to a target protein ligand.
  • HY-15238A
    ST-836 hydrochloride

    		Dopamine Receptor Neurological Disease
    ST-836 hydrochloride is a dopamine receptor ligand; Antiparkinsonian agent.
  • HY-15238
    ST-836

    		Dopamine Receptor Neurological Disease
    ST-836 is a dopamine receptor ligand; Antiparkinsonian agent.
  • HY-23095
    Thalidomide-5-OH

    		Ligand for E3 Ligase Cancer
    Thalidomide-5-OH is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-OH can be connected to the ligand for protein by a linker to form PROTACs.
  • HY-130708
    UNC6852

    		Histone Methyltransferase PROTAC Cancer
    UNC6852 is a selective rolycomb repressive complex 2 (PRC2) degrader based on PROTAC and contains an EED (embryonic ectoderm development) ligand and a VHL ligand, with an IC50 of 247 nM for EED.
  • HY-136237
    Thalidomide-NH-C5-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate
    Thalidomide-NH-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-136164
    VH032-OH

    		Ligand for E3 Ligase Cancer
    VH032-OH is the VH032-based VHL ligand. VH032-OH can be connected to the ligand for protein by a linker to form PROTACs.
  • HY-111879
    Biotin-BS

    		SNIPER Cancer
    Biotin-BS contains two different ligands, methyl-bestatin (MeBS) for cIAP1 and biotin, which are connected by linkers. MeBS as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase.
  • HY-130964B
    Thalidomide-PEG4-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-15583
    Auristatin F

    		Microtubule/Tubulin ADC Cytotoxin Cancer
    Auristatin F is a potent cytotoxin. Auristatin F, a potent microtubule inhibitor and vascular damaging agent (VDA), can be used in antibody-drug conjugates (ADC).
  • HY-100583
    (-)-(S)-Equol

    		Estrogen Receptor/ERR Endogenous Metabolite Cancer Metabolic Disease Neurological Disease
    (-)-(S)-Equol is a high affinity ligand for estrogen receptor β with a Ki of 0.73 nM.
  • HY-106547
    Rilmazafone

    		GABA Receptor Neurological Disease
    Rilmazafone is a benzodiazepine ω ligand with sedative and hypnotic effects.
  • HY-111878
    BzNH-BS

    		SNIPER Cancer
    BzNH-BS contains two different ligands, methyl-bestatin (MeBS) for cIAP1 and benzoyl-amide, which are connected by linkers. MeBS as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase.
  • HY-130639
    Thalidomide-NH-C4-NH-Boc

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-NH-C4-NH-Boc (compound 15) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-129704
    Thalidomide-NH-C6-NH2

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-NH-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-136162
    Thalidomide 4'-ether-alkylC2-amine hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide 4'-ether-alkylC2-amine hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-129704A
    Thalidomide-NH-C6-NH2 TFA

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-NH-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
  • HY-110392
    CMP8

    		Estrogen Receptor/ERR Cancer
    CMP8, a selective ligand for estrogen receptor, binds to the mutant estrogen receptor ligand binding domain (ERLBD). CMP8 exhibits IC50 values of 29 nM , 41 nM, 1100 nM and 2200 nM for MGERα, MGRERα, hERα and hERβ, respectively.
  • HY-136161
    Pomalidomide-PEG6-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-PEG6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 6-unit PEG linker used in PROTAC technology.
  • HY-128767
    VH032-PEG3-acetylene

    		E3 Ligase Ligand-Linker Conjugate Cancer
    VH032-PEG3-acetylene is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.
  • HY-75035
    Calcipotriol Impurity C

    		VD/VDR Inflammation/Immunology
    Calcipotriol Impurity C is the impurity of Calcipotriol, Calcipotriol is a ligand of VDR-like receptors.
  • HY-12452
    DPN

    Diarylpropionitrile

    		 Estrogen Receptor/ERR Neurological Disease
    DPN (Diarylpropionitrile) is a non-steroidal estrogen receptor β(ER β) selective ligand.
  • HY-P0183
    Nociceptin

    Orphanin FQ

    		 Opioid Receptor Neurological Disease
    Nociceptin, a heptadecapeptide, is the endogenous ligand of the nociceptin receptor, acting as a potent anti-analgesic.
  • HY-107438A
    Thalidomide-O-amido-C4-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.
  • HY-136166
    Thalidomide-NH-PEG3-propionic acid

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-NH-PEG3-propionic acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-130948B
    Thalidomide-O-C4-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate
    Thalidomide-O-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide (HY-14658) based cereblon ligand and a linker used in PROTAC technology.
  • HY-107439A
    Thalidomide-O-amido-C8-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-C8-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.
  • HY-136156
    Pomalidomide-PEG6-butyl iodide

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-PEG6-butyl iodide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 6-unit PEG linker used in PROTAC technology.
  • HY-112618B
    Thalidomide-O-amido-C6-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-C6-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.
  • HY-131159
    Thalidomide-O-C8-Boc

    		Ligand for E3 Ligase Cancer
    Thalidomide-O-C8-Boc is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-C8-Boc can be connected to the ligand for protein by a linker to form PROTACs.
  • HY-122694A
    Thalidomide-O-amido-PEG-C2-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-PEG-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.
  • HY-114420
    AP1867-2-(carboxymethoxy)

    PROTAC FKBP12-binding moiety 2

    		 FKBP Ligand for Target Protein for PROTAC Cancer
    AP1867-2-(carboxymethoxy), the AP1867 (a synthetic FKBP12 F36V-directed ligand) based moiety, binds to CRBN ligand via a linker to form dTAG molecules.
  • HY-W011051
    2-Arachidonoylglycerol

    		Cannabinoid Receptor Endogenous Metabolite Neurological Disease
    2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
  • HY-U00228
    Rilmazafone hydrochloride

    450191S

    		 GABA Receptor Neurological Disease
    Rilmazafone hydrochloride (450191S) is a benzodiazepine ω ligand with sedative and hypnotic effects.
  • HY-15265
    Impurity F of Calcipotriol

    		VD/VDR Cancer
    Impurity F of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.
  • HY-133144
    Lenalidomide-OH

    		Ligand for E3 Ligase Cancer
    Lenalidomide-OH is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC BTK degrader SJF620 (HY-133137).
  • HY-P1205A
    MCH(human, mouse, rat) TFA

    		MCHR1 (GPR24) Neurological Disease
    MCH (human, mouse, rat) TFA is a potent peptide agonist of MCH-R and exhibits binding IC50 values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHO cell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC50 values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively.
  • HY-135572
    TLX agonist 1

    		Others Cancer Neurological Disease
    TLX agonist 1 (ccrp2) is an orphan nuclear receptor tailless (TLX, NR2E1) modulator (EC50=1μM; Kd= 650 nM). TLX agonist 1 potentiates TLX transcriptional repressive activity.
  • HY-130981
    FN-1501-propionic acid

    		CDK Ligand for Target Protein for PROTAC Cancer
    FN-1501-propionic acid is a CDK2/9 ligand for PROTAC. FN-1501-propionic acid and a CRBN ligand have been used to design PROTAC CDK2/9 degrader (HY-130709).
  • HY-112599B
    Pomalidomide-PEG4-C2-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in the synthesis of PROTACs..
  • HY-122470
    Stampidine

    		Reverse Transcriptase HIV Infection
    Stampidine is a nucleoside reverse transcriptase inhibitor (NRTI) with potent and broad-spectrum anti-HIV activity. Stampidine inhibits the laboratory HIV-1 strain HTLVIIIB (B-envelope subtype) and primary clinical isolates with IC50s of 1 nM and 2 nM, respectively. Stampidine also inhibits NRTI-resistant primary clinical isolates and NNRTI-resistant clinical isolates with IC50s of 8.7 nM and 11.2 nM, respectively.
  • HY-110399
    Cirsiliol

    		Lipoxygenase Neurological Disease
    Cirsiliol is a potent and selective 5-lipoxygenase inhibitor and a competitive low affinity benzodiazepine receptor ligand.
  • HY-111663
    VL285

    		Ligand for E3 Ligase Cancer
    VL285 is a potent VHL ligand with an IC50 of 0.34 μM.
  • HY-13723
    Pimecrolimus

    SDZ-ASM 981

    		 Others Inflammation/Immunology
    Pimecrolimus is an immunophilin ligand, which binds specifically to the cytosolic receptor, immunophilin macrophilin-12.
  • HY-N0277
    Aconine

    Jesaconine

    		 NF-κB Inflammation/Immunology Cancer
    Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced NF-κB activation.
  • HY-114176B
    (S,R,S)-AHPC-C4-NH2 dihydrochloride

    VH032-C4-NH2 dihydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C4-NH2 dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.
  • HY-122710A
    Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.
  • HY-107442
    PROTAC BRD4-binding moiety 1

    		Epigenetic Reader Domain Ligand for Target Protein for PROTAC Cancer
    PROTAC BRD4-binding moiety 1 is a ligand for BRD4. PROTAC BRD4-binding moiety 1 binds to cereblon ligand via a linker to form PROTAC to degrade BRD4 (HY-133136).
  • HY-114176A
    (S,R,S)-AHPC-C4-NH2

    VH032-C4-NH2

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.
  • HY-136165
    (S,R,S)-AHPC-PEG3-propionic acid

    		E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG3-propionic acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-122825
    SNIPER(ER)-110

    		SNIPER Estrogen Receptor/ERR Cancer
    SNIPER(ER)-110 consists of a cIAP1 ligand and an estrogen ligand, connected by a linker. SNIPER(ER)-51 induces estrogen receptor (ER) protein degradation with DC50s of <3 nM and 7.7 nM after 4 h and 48 h, respectively.
  • HY-114434
    AP1867

    		FKBP Cancer
    AP1867 is a synthetic FKBP12 F36V-directed ligand.
  • HY-100486
    BTTAA

    		Others Others
    BTTAA is a Cu(I)-stabilizing ligand, whch performs potently with ubiquitin Glu18AzF.
  • HY-135324
    4,4'-Iminodiphenol

    		Estrogen Receptor/ERR Endocrinology
    4-Propionamidophenol (compound 4a) is an inactive estrogen receptor ligand based on the diphenylamine skeleton.
  • HY-116677
    Tris(benzyltriazolylmethyl)amine

    TBTA

    		 Others Others
    Tris(benzyltriazolylmethyl)amine (TBTA) is a ligand that acts as a biochemical tool for the tagging of proteins and enzymes.
  • HY-B1033
    Metergoline

    		5-HT Receptor Neurological Disease
    Metergoline is a psychoactive drug of the ergoline chemical class which acts as a ligand for various serotonin and dopamine receptors.
  • HY-130648
    Thalidomide-NH-PEG7

    		Drug-Linker Conjugates for ADC Cancer
    Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate for ADC. Thalidomide-NH-PEG7 can be connected to the ligand for protein by a linker to form PROTAC iRucaparib-AP6, a highly specific PARP1 degrader.
  • HY-43722
    Lenalidomide-Br

    		Ligand for E3 Ligase Cancer
    Lenalidomide-Br (Compound 41) is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-Br can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC STAT3 degrader SD-36 (HY-129602).
  • HY-129703B
    Thalidomide-NH-PEG2-C2-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.
  • HY-107440A
    Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-129703
    Thalidomide-NH-PEG2-C2-NH2

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.
  • HY-130269
    β-Naphthoflavone-CH2-OH

    β-NF-CH2-OH

    		 Ligand for E3 Ligase Cancer
    β-Naphthoflavone-CH2-OH (β-NF-CH2-OH) is a ligand for arylhydrocarbon receptor (AhR) E3 ligase. β-Naphthoflavone-CH2-OH can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs (e.g., β-naphthoflavone-JQ1) that recruit the AhR E3 ligase complex by incorporating AhR ligands into chimeric molecules. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .
  • HY-19945
    DAA-1106

    		GABA Receptor Neurological Disease
    DAA1106 is a potent and selective ligand for peripheral benzodiazepine receptor (PBR), as a potent and selective agonist at the peripheral benzodiazepine receptor.
  • HY-15527
    Emapunil

    AC-5216; XBD-173

    		 Others Neurological Disease
    Emapunil(AC-5216;XBD-173) is a translocator protein [TSPO (18 kDa)] ligand.
  • HY-32339
    Maxacalcitol

    22-Oxacalcitriol

    		 VD/VDR Metabolic Disease
    Maxacalcitol (22-Oxacalcitriol) is non-calcemic vitamin D3 analog and ligand of VDR-like receptors.
  • HY-U00250
    β-Amino Acid Imagabalin Hydrochloride

    PD-0332334

    		 Calcium Channel Neurological Disease
    β-Amino Acid Imagabalin Hydrochloride (PD-0332334) is a ligand for the α2δ subunit of the voltage-dependent calcium channel.
  • HY-101601
    Bamirastine

    TAK-427

    		 Histamine Receptor Inflammation/Immunology Endocrinology
    Bamirastine inhibits ligand binding to recombinant human histamine H1 receptors (rhH1R) with an IC50 value of 17.3 nM.
  • HY-P1380A
    Difopein TFA

    		Apoptosis Cancer
    Difopein (TFA), a specific and competitive inhibitor of 14-3-3 protein (a highly conserved eukaryotic regulatory molecule), blocking the ability of 14-3-3 to bind to target proteins and inhibits 14-3-3/Ligand interactions. Difopein (TFA) leads to induction of apoptosis and enhances the ability of cisplatin to kill cells.
  • HY-129703A
    Thalidomide-NH-PEG2-C2-NH2 TFA

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.
  • HY-131190
    N-Boc-SBP-0636457-O-C3-COOH

    		E3 Ligase Ligand-Linker Conjugate Cancer
    N-Boc-SBP-0636457-OH is a synthesized E3 ligase ligand-linker conjugate that incorporates IAP ligand and a linker. N-Boc-SBP-0636457-OH can be used to design a PROTAC Bcl-xL degrader-1 (HY-131188).
  • HY-69220
    7-Octynoic acid

    		PROTAC Linker Cancer
    7-Octynoic acid (compound 42) is a PROTAC linker and can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-11007
    GNF-2

    		Bcr-Abl SARS-CoV Cancer
    GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of Bcr-Abl. GNF-2 inhibits Ba/F3.p210 proliferation with an IC50 of 138 nM .
  • HY-101861
    Miridesap

    CPHPC; Ro63-8695; GSK2315698

    		 Others Neurological Disease
    Miridesap is a ligand for serum amyloid P component (SAP) and intends to inhibit and dissociate SAP binding to amyloid fibrils and tangles.
  • HY-17571
    Oxytocin

    α-Hypophamine; Oxytocic hormone

    		 Oxytocin Receptor Endocrinology
    Oxytocin (α-Hypophamine) is a mammalian neurohypophysial hormone; its actions are mediated by specific, high-affinity oxytocin receptors; ligand of oxytocin receptor.
  • HY-17571A
    Oxytocin acetate

    α-Hypophamine acetate; Oxytocic hormone acetate

    		 Oxytocin Receptor Endocrinology
    Oxytocin acetate (α-Hypophamine acetate) is a mammalian neurohypophysial hormone; its actions are mediated by specific, high-affinity oxytocin receptors; ligand of oxytocin receptor.
  • HY-15264
    MC 1046

    Impurity A of Calcipotriol

    		 VD/VDR Cancer
    MC 1046(Impurity A of Calcipotriol) is an impurity of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.
  • HY-128128
    ASN04421891

    		Others Neurological Disease
    ASN04421891 is a potent GPR17 receptor modulator, with an EC50 of 3.67 nM in [35S]GTPγS binding assay. ASN04421891 can be used for neurodegenerative diseases research.
  • HY-18370
    HIF-2α-IN-3

    		HIF/HIF Prolyl-Hydroxylase Cancer
    HIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α (HIF-2α), exhibits an IC50 of 0.4 µM and a KD of 1.1 µM. Anticancer agent.
  • HY-108258A
    PSN 375963 hydrochloride

    		GPR119 Endocrinology
    PSN 375963 hydrochloride is a potent GPR119 agonist, with EC50s of 8.4 and 7.9 μM for human and mouse GPR119, respectively. PSN 375963 hydrochloride shows similar potency to the endogenous agonist oleoylethanolamide (OEA).
  • HY-130197
    Lipoamido-PEG4-azide

    		PROTAC Linker Cancer
    Lipoamido-PEG4-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
  • HY-125845A
    (S,S,S)-AHPC hydrochloride

    (S,S,S)-VH032-NH2 hydrochloride

    		 Ligand for E3 Ligase Cancer
    (S,S,S)-AHPC hydrochloride is a von Hippel-Lindau (VHL) amino building block. (S,S,S)-AHPC is a ligand used as a negative control for (S,R,S)-AHPC. (S,R,S)-AHPC is the VH032-based VHL ligand used in the recruitment of the VHL protein.
  • HY-131189
    N-Boc-SBP-0636457-OH

    		Ligand for E3 Ligase Cancer
    N-Boc-SBP-0636457-OH, a ligand for E3 ubiquitin ligase, is used in the recruitment of IAP E3 ligases. N-Boc-SBP-0636457-OH can be connected to the ligand for Bcl-xL by a linker to form PROTAC Bcl-xL degrader-1 (HY-131188).
  • HY-130849
    (S,R,S)-AHPC-Me-C5-COOH

    		E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-Me-C5-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C5-COOH can be used in PROTAC DT2216 (HY-130604).
  • HY-131186
    Pomalidomide-amido-C3-piperazine-N-Boc

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-amido-C3-piperazine-N-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183).
  • HY-112398
    GSK1379725A

    		Epigenetic Reader Domain Others
    GSK1379725A is a selective BPTF ligand with a Kd of 2.8 uM, showing no binding activity for Brd4.
  • HY-111850
    Bestatin-amido-Me

    PROTAC IAP binding moiety 1

    		 Ligand for E3 Ligase Cancer
    Bestatin-amido-Me, the Bestatin-based IAP ligand, binds to ABL inhibitor via a linker to form SNIPER.
  • HY-P2267
    LDV

    		Integrin
    LDV, a non-fluorescent derivative of LDV FITC, is a α4β1 integrin (VLA-4) ligand (Kd ~ 12 nM).
  • HY-100275
    MK-3328

    		Amyloid-β Neurological Disease
    MK-3328 is a β-Amyloid PET ligand, which exhibits high binding potency with an IC50 of 10.5 nM.
  • HY-15266
    24R-Calcipotriol

    PRI 2202; Impurity D of Calcipotriol

    		 VD/VDR Cancer
    24R-Calcipotriol(PRI 2202) is an impurity of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.
  • HY-130641
    Br-C10-methyl ester

    		PROTAC Linker Cancer
    Br-C10-methyl ester is a PROTAC linker, which refers to the alkyl/ether composition. Br-C10-methyl ester is used in the synthesis of a series of PROTACs (MS432).  PROTACs contain two different ligands connected by a linker; one is the VHL ligand portion and the other is for the target protein.
  • HY-107444
    PROTAC Her3-binding moiety 1

    		Ligand for Target Protein for PROTAC Cancer
    PROTAC HER3-binding moiety 1 (compound 1b) is a Her3 Ligand for PROTAC.
  • HY-A0077AS
    Perphenazine D8 Dihydrochloride

    		5-HT Receptor Adrenergic Receptor Dopamine Receptor Histamine Receptor Endocrinology Neurological Disease
    Perphenazine D8 Dihydrochloride is the deuterium labeled Perphenazine, which is a typical antipsychotic drug(5-HT, Dopamine receptor ligand).
  • HY-129941
    (S,R,S)-AHPC-C10-NH2

    VH032-C10-NH2

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C10-NH2 (VH032-C10-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC.
  • HY-129941A
    (S,R,S)-AHPC-C10-NH2 dihydrochloride

    VH032-C10-NH2 dihydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C10-NH2 dihydrochloride (VH032-C10-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC.
  • HY-131231
    Thalidomide-NH-PEG3-CH2CHO

    		Ligand for E3 Ligase Cancer
    Thalidomide-NH-PEG3-CH2CHO is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-NH-PEG3-CH2CHO can be connected to the ligand for protein by a linker to form PROTAC BCL-XL degrader XZ739 (HY-133557).
  • HY-130854
    Thalidomide-NH-C6-NH-Boc

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-NH-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used for MI-389 (compound 22) synthesis. MI-389 is a potent phthalimide PROTAC degrader based on the multi-targeted receptor tyrosine kinase inhibitor sunitinib (HY-10255A).
  • HY-130847
    (S,R,S)-AHPC-Me-C10-NH2

    		E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-Me-C10-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C10-NH2 can be used in PROTAC MS432 (HY-130602).
  • HY-P1186
    Eledoisin Related Peptide

    Eledoisin-Related Peptide; Eledoisin RP

    		 Neurokinin Receptor Neurological Disease
    Eledoisin Related Peptide is a Substance P analog that excites neurons and triggers behavioral responses. Eledoisin Related Peptide is also a tachykinin receptor ligand.
  • HY-16785
    Veledimex

    INXN-1001; RG-115932

    		 Cytochrome P450 Interleukin Related Cancer Inflammation/Immunology
    Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5.
  • HY-16785A
    Veledimex racemate

    INXN-1001 racemate; RG-115932 racemate

    		 Interleukin Related Cytochrome P450 Cancer Inflammation/Immunology
    Veledimex racemate (INXN-1001 racemate) is the racemate of veledimex. Veledimex is an orally available, small-molecule activator ligand for the RheoSwitch Therapeutic System.
  • HY-P0031
    Cyclo(RADfK)

    		Integrin Others
    Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.
  • HY-P1037
    Motilin (26-47), human, porcine

    		Motilin Receptor Others
    Motilin (26-47), human, porcine is an endogenous motilin receptor ligand with Ki and EC50 of 2.3 nM and 0.3 nM in a Chinese hamster ovary cell line.
  • HY-N2388
    Auraptene

    		MMP Inflammation/Immunology Cancer
    Auraptene is the most abundant naturally occurring geranyloxycoumarin. Auraptene is primarily isolated from plants in the Rutaceae family, such as citrus fruits. Auraptene decreases the secretion of matrix metalloproteinase 2 (MMP-2) as well as key inflammatory mediators, including IL-6, IL-8, and chemokine (C-C motif) ligand-5(CCL5).
  • HY-130853
    Thalidomide-NH-PEG2-C2-NH-Boc

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-NH-PEG2-C2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a PEG linker used for dBRD9 (compound 6) synthesis. dBRD9 is a selective BRD9 probe PROTAC degrader for the study of BAF complex biology.
  • HY-111844
    PROTAC RAR Degrader-1

    		SNIPER PROTAC RAR/RXR Cancer
    PROTAC RAR Degrader-1 comprises a cIAP1 ligand binding group, a linker and a RAR ligand binding group. PROTAC RAR Degrader-1 is an RAR degrader. Maximal RAR degradation at 30 μM concentration in HT1080 cells. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs).
  • HY-103603B
    (S,R,S)-AHPC-PEG2-NH2 dihydrochloride

    VH032-PEG2-NH2 dihydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG2-NH2 dihydrochloride (VH032-PEG2-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.
  • HY-111872
    SNIPER(ABL)-020

    		SNIPER Bcr-Abl Cancer
    SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein.
  • HY-111857
    Dasatinib carbaldehyde

    BMS-354825 carbaldehyde; PROTAC ABL binding moiety 4

    		 Ligand for Target Protein for PROTAC Cancer
    Dasatinib carbaldehyde (BMS-354825 carbaldehyde), the Dasatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .
  • HY-112895A
    (R)-UT-155

    		Androgen Receptor Cancer
    (R)-UT-155 (compound 11) is a selective androgen receptor degrader (SARD) ligand. Less active than the S-isomer.
  • HY-110385
    cGAMP disodium

    Cyclic GMP-AMP disodium; 3',3'-cGAMP disodium

    		 Endogenous Metabolite Inflammation/Immunology
    cGAMP disodium (Cyclic GMP-AMP disodium) is the third cyclic dinucleotide (CDN) to be discovered in bacteria. cGAMP disodium is an effective adjuvant for sublingual vaccination capable of promoting broad immunity including serum anti-PA neutralizing and anti-PA SIgA responses in airway secretions.
  • HY-34544
    2-Hexylthiophene

    		Others Others
    2-Hexylthiophene is an extremely weak basic heteroaromatic compound. 2-Hexylthiophene can be used to modify and improve the molar absorption coefficient of ruthenium sensitizer
  • HY-130988
    Ipatasertib-NH2

    GDC-0068-NH2; RG7440-NH2

    		 Ligand for Target Protein for PROTAC Cancer
    Ipatasertib-NH2 (GDC-0068-NH2;RG7440-NH2) is a ligand for target protein AKT for PROTAC, binds to lenalidomide, a ligand of ubiquitin E3 ligase cereblon (CRBN), via a ten-hydrocarbon linker to form INY-03-041 (HY-133120) to degrade AKT.
  • HY-P9904
    Atezolizumab

    MPDL3280A

    		 PD-1/PD-L1 Cancer
    Atezolizumab is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
  • HY-15420
    BML-190

    Indomethacin morpholinylamide; IMMA

    		 Cannabinoid Receptor Cancer
    BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).
  • HY-130715
    tert-Butyl 11-aminoundecanoate

    		PROTAC Linker Cancer
    tert-Butyl 11-aminoundecanoate (compound 6b) is a PROTAC linker, which refers to the PEG composition. tert-Butyl 11-aminoundecanoate can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-111858
    SNIPER(ABL)-050

    		SNIPER Bcr-Abl Cancer
    SNIPER(ABL)-050, conjugating Imatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein.
  • HY-111852
    GNF5-amido-Me

    PROTAC ABL binding moiety 2

    		 Ligand for Target Protein for PROTAC Cancer
    GNF5-amido-Me, the GNF5 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.
  • HY-111853
    MV-1-NH-Me

    PROTAC IAP binding moiety 2

    		 Ligand for E3 Ligase Cancer
    MV-1-NH-Me, the MV-1 based IAP ligand, binds to ABL inhibitor via a linker to form SNIPER.
  • HY-13751
    SR-31747

    		Sigma Receptor Inflammation/Immunology
    SR-31747 is a sigma ligand with immunosuppressive and anti-inflammatory properties. SR-31747 blocks cell proliferation by inhibiting sterol isomerase.
  • HY-122577
    EN40

    		Aldehyde Dehydrogenase (ALDH) Cancer
    EN40 is a potent, selective aldehyde dehydrogenase 3A1 (ALDH3A1) inhibitor as a covalent ligand, exhibits an IC50 value of 2 uM
  • HY-124625
    BI-4464

    		FAK Ligand for Target Protein for PROTAC Cancer
    BI-4464 is a highly selective ATP competitive inhibitor of PTK2/FAK, with an IC50 of 17 nM. A PTK2 ligand for PROTAC.
  • HY-129774
    Phthalimide-PEG4-MPDM-OH

    		PROTAC Linker Cancer
    Phthalimide-PEG4-MPDM-OH is a PROTAC linker, which refers to the PEGs composition. Phthalimide-PEG4-MPDM-OH can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-130617
    Pomalidomide-amido-C1-Br

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-amido-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-amido-C1-Br can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1 (HY-111758). PROTAC B-Raf degrader 1 has anti-cancer activity.
  • HY-129773
    Phthalimide-PEG4-PDM-OTBS

    		PROTAC Linker Cancer
    Phthalimide-PEG4-PDM-OTBS is a PROTAC linker, which refers to the PEGs composition. Phthalimide-PEG4-PDM-OTBS can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-N4194
    Glabrone

    		PPAR Metabolic Disease
    Glabrone is an isoflavone isolated from Glycyrrhiza glabra roots. Glabrone exhibits anti-influenza activity and significant PPAR-γ ligand-binding activity.
  • HY-B2087
    Glycerol phenylbutyrate

    HPN-100

    		 Sigma Receptor Cardiovascular Disease
    Glycerol phenylbutyrate is a sigma-2 (σ2) receptor ligand, with a pKi of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug.
  • HY-129405
    N-(Ketocaproyl)-D,L-homoserine lactone

    		Bacterial Infection
    N-(Ketocaproyl)-D,L-homoserine lactone is a natural, very active ligand of LuxR. N-(Ketocaproyl)-D,L-homoserine lactone is a quorum sensing (QS) autoinducer.
  • HY-111413
    c(phg-isoDGR-(NMe)k)

    		Integrin Cancer
    c(phg-isoDGR-(NMe)k) is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM.
  • HY-111849
    Imatinib carbaldehyde

    CGP-57148B carbaldehyde; STI571 carbaldehyde; PROTAC ABL binding moiety 1

    		 Ligand for Target Protein for PROTAC Cancer
    Imatinib carbaldehyde (CGP-57148B carbaldehyde), the Imatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.
  • HY-13956
    Pioglitazone

    U 72107

    		 PPAR Ferroptosis Metabolic Disease Cancer
    Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
  • HY-15329
    Maxacalcitol-D6

    		VD/VDR Metabolic Disease
    Maxacalcitol-D6 is the deuterated form of Maxacalcitol (22-Oxacalcitriol), which is a non-calcemic vitamin D3 analog and VDR ligand of VDR-like receptors.
  • HY-111851
    SNIPER(ABL)-049

    		SNIPER Bcr-Abl Cancer
    SNIPER(ABL)-049, conjugating Imatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 100 μM.
  • HY-136055
    (S,R,S)-AHPC-C5-COOH

    VH032-C5-COOH

    		 E3 Ligase Ligand-Linker Conjugate HIF/HIF Prolyl-Hydroxylase Cancer
    (S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized E3 ligase ligand-linker conjugate, contains the VH032 VHL-based ligand and a linker to form PROTACs. VH-032 is a selective and potent inhibitor of VHL/HIF-1α interaction with a Kd of 185 nM, has the potential for the study of anemia and ischemic diseases.
  • HY-P0272
    Peptide T

    		HIV Infection
    Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.
  • HY-107447
    N-Deshydroxyethyl Dasatinib

    N-Deshydroxyethyl BMS-354825

    		 Ligand for Target Protein for PROTAC Cancer
    N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL.
  • HY-U00180
    KF21213

    		Adenosine Receptor Neurological Disease
    KF21213 is a highly selective ligand for mapping CNS adenosine A2A receptors. KF21213 shows a high affinity for the adenosine A2A receptors (Ki=3.0 nM).
  • HY-136280
    Panamesine

    EMD 57445

    		 Sigma Receptor Neurological Disease
    Panamesine (EMD 57445) is a sigma receptor ligand, which has a high affinity (IC50 6 nM) and selectivity for sigma binding sites. Panamesine is a potential atypical neuroleptic agent.
  • HY-111860
    SNIPER(ABL)-013

    		SNIPER Bcr-Abl Cancer
    SNIPER(ABL)-013, conjugating GNF5 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 20 μM.
  • HY-111413A
    c(phg-isoDGR-(NMe)k) TFA

    		Integrin Cancer
    c(phg-isoDGR-(NMe)k) TFA is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM.
  • HY-13751A
    SR-31747 free base

    		Sigma Receptor Inflammation/Immunology
    SR-31747 free base is a sigma ligand with immunosuppressive and anti-inflammatory properties. SR-31747 blocks cell proliferation by inhibiting sterol isomerase.
  • HY-130640
    (S,R,S)-AHPC-Me-C7 ester

    		E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-Me-C7 ester is a E3 ligase ligand-linker conjugate used to synthesise BCL-XL PROTAC degraders.
  • HY-P1123
    MEDICA16

    		ATP Citrate Lyase GPR40 GPR120 Metabolic Disease
    MEDICA16, an ATP-citrate lyase inhibitor, significantly reduces intracellular TG content in gastrocnemius muscle, and this reduction is accompanied by an increase in insulin sensitivity. MEDICA16 is a selective agonist for GPR40 as well as selective partial agonists for GPR120.
  • HY-129364
    5-A-RU hydrochloride

    5-Amino-6-(D-ribitylamino)uracil hydrochloride

    		 Others Inflammation/Immunology
    5-A-RU hydrochloride (5-Amino-6-(D-ribitylamino)uracil hydrochloride), a precursor of bacterial Riboflavin, is a mucosal-associated invariant T (MAIT) cells activator. 5-A-RU hydrochloride forms potent MAIT-activating antigens via non-enzymatic reactions with small molecules, such as glyoxal and methylglyoxal, which are derived from other metabolic pathways.
  • HY-P0023
    Cyclo(-RGDfK)

    		Integrin Cancer
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
  • HY-P1299A
    UFP-101 TFA

    		Opioid Receptor Neurological Disease
    UFP-101 TFA is a potent, selective, and competitive antagonist of the NOP receptor, with a pKi of 10.24. UFP-101 TFA displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 TFA shows antidepressant-like effect.
  • HY-120738
    p-MPPI hydrochloride

    		5-HT Receptor Neurological Disease
    p-MPPI hydrochloride is a selective 5-HT1A receptor antagonist with high affinity for 5-HT1A receptors. p-MPPI hydrochloride can crosses the blood-brain barrier, and has clear antidepressant and anxiolytic-like effects.
  • HY-P1299
    UFP-101

    		Opioid Receptor Neurological Disease
    UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pKi of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect.
  • HY-P0023A
    Cyclo(-RGDfK) TFA

    		Integrin Cancer
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
  • HY-129364A
    5-A-RU

    5-Amino-6-(D-ribitylamino)uracil

    		 Others Inflammation/Immunology
    5-A-RU (5-Amino-6-(D-ribitylamino)uracil), a precursor of bacterial Riboflavin, is a mucosal-associated invariant T (MAIT) cells activator. 5-A-RU forms potent MAIT-activating antigens via non-enzymatic reactions with small molecules, such as glyoxal and methylglyoxal, which are derived from other metabolic pathways.
  • HY-12436
    NTRC-824

    		Neurotensin Receptor Neurological Disease
    NTRC-824 (Compound 5) is a potent, selective and neurotensin-like nonpeptide neurotensin receptor type 2 (NTS2) antagonist with an IC50 of 38 nM and a Ki of 202 nM. NTRC-824 is >150-fold selectivity for NTS2 over NTS1 (Ki >30 μM).
  • HY-129772
    Phthalimide-PEG3-C2-OTs

    		PROTAC Linker Cancer
    Phthalimide-PEG3-C2-OTs (Compound 5) is a PROTAC linker, which refers to the PEGs composition. Phthalimide-PEG3-C2-OTs can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-129619
    SNIPER(ER)-87

    		SNIPER Estrogen Receptor/ERR Cancer
    SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor α (ERα) ligand 4-hydroxytamoxifen by a PEG linker, and efficiently degrades the ERα protein (IC50=0.097 μM). SNIPER(ER)-87 preferentially recruits XIAP to ERα in the cells, and XIAP is the primary E3 ubiquitin ligase responsible for the SNIPER(ER)-87-induced ERα degradation.
  • HY-P0272A
    Peptide T TFA

    		HIV Infection
    Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.
  • HY-15594
    Phen-DC3

    		DNA/RNA Synthesis Cancer
    Phen-DC3 is a G-quadruplex (G4) specific ligand which can inhibit FANCJ and DinG helicases with IC50s of 65±6 and 50±10 nM, respectively.
  • HY-15043
    ELN-441958

    		Bradykinin Receptor Cancer Endocrinology
    ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM.
  • HY-111855
    HG-7-85-01-Decyclopropane

    PROTAC ABL binding moiety 3

    		 Ligand for Target Protein for PROTAC Cancer
    HG-7-85-01-Decyclopropane, the HG-7-85-01 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .
  • HY-111859
    SNIPER(ABL)-058

    		SNIPER Bcr-Abl Cancer
    SNIPER(ABL)-058, conjugating Imatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 μM.
  • HY-111854
    SNIPER(ABL)-015

    		SNIPER Bcr-Abl Cancer
    SNIPER(ABL)-015, conjugating GNF5 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 5 μM .
  • HY-102023
    GNF351

    		Aryl Hydrocarbon Receptor Others
    GNF351 is a full aryl hydrocarbon receptor (AHR) antagonist. GNF351 competes with a photoaffinity AHR ligand for binding to the AHR with an IC50 of 62 nM. GNF351 is minimal toxicity in mouse or human keratinocytes.
  • HY-130852
    CDK9-IN-11

    		CDK Ligand for Target Protein for PROTAC Cancer
    CDK9-IN-11 is a potent CDK9 inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628).
  • HY-106025
    Radequinil

    AC-3933

    		 GABA Receptor Neurological Disease
    Radequinil (AC-3933) is a benzodiazepine receptor (BzR) partial inverse agonist. AC-3933 binds to GABA(-) and GABA(+) ligand with Kis of 5.15 and 6.11 nM, respectively.
  • HY-N6253
    Pinoresinol

    (+)-Pinoresinol

    		 Apoptosis Cancer
    Pinoresinol is a lignol of plant origin serving for defense in a caterpillar. Pinoresinol drastically sensitizes cancer cells against TNF-related apoptosis-inducing ligand (TRAIL) -induced apoptosis.
  • HY-15594A
    Phen-DC3 Trifluoromethanesulfonate

    Phen-DC3 Triflate

    		 G-quadruplex Cancer
    Phen-DC3 Trifluoromethanesulfonate is a G-quadruplex (G4) specific ligand which can inhibit FANCJ and DinG helicases with IC50s of 65±6 and 50±10 nM, respectively.
  • HY-114306
    EC0489

    		Antifolate Cancer
    EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor. Small molecule-drug conjugate (SMDC).
  • HY-111873
    SNIPER(ABL)-019

    		SNIPER Bcr-Abl Cancer
    SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 0.3 μM.
  • HY-130850
    CDK9-IN-10

    		CDK Ligand for Target Protein for PROTAC Cancer
    CDK9-IN-10 is a potent CDK9 inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811).
  • HY-40178
    NH2-C4-NH-Boc

    		PROTAC Linker Cancer
    NH2-C4-NH-Boc (compound 15) is a PROTAC linker, which refers to the Alkyl/ether composition. NH2-C4-NH-Boc can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-108496
    Sphingosine-1-phosphate

    S1P

    		 Endogenous Metabolite LPL Receptor Endocrinology
    Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca 2+ as an extracellular ligand for G protein-coupled receptors. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids.
  • HY-111861
    SNIPER(ABL)-024

    		SNIPER Bcr-Abl Cancer
    SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 5μM.
  • HY-P0224
    N-Formyl-Met-Leu-Phe

    fMLP; N-Formyl-MLF

    		 TNF Receptor Inflammation/Immunology
    N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit TNF-alpha secretion.
  • HY-130845
    AR antagonist 1

    		Ligand for E3 Ligase Cancer
    AR antagonist 1 (compound 29) is a potent androgen receptor (AR) antagonist and binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC ARD-266 (HY-133020).
  • HY-100686
    U93631

    		GABA Receptor Neurological Disease
    U93631 is a GABAA receptor ligand of novel chemical structure with IC50 of 100 nM,and has been shown to induce a rapid, time-dependent decay of GABA-induced whole-cell Cl-currents in recombinant GABAA receptors.
  • HY-129652
    Halo PROTAC 1

    		PROTAC Autophagy Cancer
    Halo PROTAC 1 is a PROTAC, which is a ligand having activity to bind to an intracellular proteins fused with HaloTag and a structure having activity to induce autophagy of an intracellular molecule are linked via a PEG linker.
  • HY-124673
    AF40431

    		Neurotensin Receptor Neurological Disease
    AF40431, the first reported small-molecule ligand of sortilin, has an IC50 of 4.4 µM and a Kd of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilin.
  • HY-111862
    SNIPER(ABL)-044

    		SNIPER Bcr-Abl Cancer
    SNIPER(ABL)-044, conjugating HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 μM.
  • HY-135345
    PROTAC FKBP Degrader-3

    		PROTAC FKBP Cancer
    PROTAC FKBP Degrader-3 is a PROTAC that comprises a FKBP ligand binding group, a linker and an VHL binding group. PROTAC FKBP Degrader-3 is a potent FKBP degrader.
  • HY-13992
    AP20187

    B/B Homodimerizer

    		 FKBP Metabolic Disease
    AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.
  • HY-112617B
    Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride incorporates an E3 ligase ligand and a linker, can be an immunomodulater for the treatment of cancer.
  • HY-16785B
    Veledimex (S enantiomer)

    INXN-1001 (S enantiomer); RG-115932 (S enantiomer)

    		 Interleukin Related Cytochrome P450 Cancer
    Veledimex S enantiomer (INXN-1001 S enantiomer) is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5.
  • HY-101622
    5-HT6/7 antagonist 1

    		5-HT Receptor Dopamine Receptor
    5-HT6/7 antagonist 1 is a multifunctional ligand that antagonizes 5-HT6/7/2A and D2 receptors, without interacting with M1 receptors and hERG channels.
  • HY-13943
    CNX-774

    		Btk Cancer
    CNX-774 is a potent, selective, and orally available small molecule inhibitor of Btk (IC50< 1 nM) that forms a ligand-directed covalent bond with Cys-481, a non-conserved amino acid within the active site of the enzyme.
  • HY-101026
    CCT251236

    		HSP Cancer
    CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an IC50 of 19 nM for inhibition of HSF1-mediated HSP72 induction.
  • HY-P1125
    4-CMTB

    		Others Others
    4-CMTB is a selective free fatty acid receptor 2 (FFA2/GPR43) agonist and a positive allosteric modulator (pEC50=6.38).
  • HY-121295
    Roseoflavin

    		Bacterial Infection
    Roseoflavin, a natural pigment originally isolated from Streptomyces davawensis, is an antimetabolite analog of Riboflavin and flavin mononucleotide that has antimicrobial properties.
  • HY-130618
    Boc-C1-PEG3-C4-OH

    		PROTAC Linker Cancer
    Boc-C1-PEG3-C4-OH is a PROTAC linker, which refers to the Alkyl/ether composition. Boc-C1-PEG3-C4-OH can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-19567
    PK 11195

    RP 52028

    		 Parasite Infection
    PK 11195 (RP 52028) is a ligand of translocator protein (TSPO), which targets Leishmania chemotherapy, with IC50s of 14.2 μM, 8.2 μM, 3.5 μM for L. amazonensis, L. major and L. braziliensis, respectively.
  • HY-111863
    SNIPER(ABL)-047

    		SNIPER Bcr-Abl Cancer
    SNIPER(ABL)-047, conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 2 μM.
  • HY-123937
    THAL-SNS-032

    		PROTAC CDK Cancer
    THAL-SNS-032 is a selective CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).
  • HY-130714
    TD-165

    		PROTAC Cancer
    TD-165 is a PROTAC-based cereblon (CRBN) degrader. TD-165 comprises a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group.
  • HY-108477
    TMPyP4 tosylate

    TMP 1363

    		 G-quadruplex Telomerase Cancer
    TMPyP4 tosylate (TMP 1363) is a quadruplex-specific ligand, which inhibits the interaction between G-quadruplexes and IGF-1. TMPyP4 tosylate (TMP 1363) is a telomerase inhibitor with antitumor effects in osteosarcoma cell lines.
  • HY-128845
    PROTAC CRBN Degrader-1

    		PROTAC Cancer
    PROTAC CRBN Degrader-1 comprises a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group. PROTAC CRBN Degrader-1 is an cereblon (CRBN) degrader.
  • HY-12650
    Mirogabalin

    DS5565

    		 Calcium Channel Neurological Disease
    Mirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand characterized by high potency and selectivity to the α2δ-1 subunit of voltage-sensitive calcium channel complexes in the CNS.
  • HY-N6777
    Penicillic acid

    		Caspase Bacterial Apoptosis Antibiotic Cancer Infection
    Penicillic acid is a polyketide mycotoxin produced by several species of Aspergillus and Penicillium, which exhibits cytotoxicity in rat alveolar macrophages (AM) in vitro. Penicillic acid inhibits Fas ligand-induced apoptosis by blocking self-processing of caspase-8.
  • HY-111871
    SNIPER(ABL)-033

    		SNIPER Bcr-Abl Cancer
    SNIPER(ABL)-033, conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 0.3 μM.
  • HY-136006
    (S,R,S)-AHPC-C6-NH2 dihydrochloride

    VH032-C6-NH2 dihydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer Inflammation/Immunology
    (S,R,S)-AHPC-C6-NH2 dihydrochloride (VH032-C6-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 dihydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1.
  • HY-130987
    Lenalidomide-C9-aldehyde

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Lenalidomide-C9-aldehyde is a synthesized E3 ligase ligand-linker conjugate that incorporates the Lenalidomide based cereblon ligand and a linker. Lenalidomide-C9-aldehyde can be used in the synthesis of a series of PROTACs, such as INY-03-041 (HY-133120). INY-03-041 is a potent, highly selective and PROTAC-based pan-Akt degrader. INY-03-041 inhibits Akt1, Akt2 and Akt3 with IC50s of 2.0 nM, 6.8 nM and 3.5 nM, respectively.
  • HY-133487B
    (S,R,S)-AHPC-C8-NH2

    VH032-C8-NH2

    		 E3 Ligase Ligand-Linker Conjugate Cancer Inflammation/Immunology
    (S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1.
  • HY-130814
    Thalidomide-NH-C4-NH2 TFA

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-NH-C4-NH2 TFA (compound 29c) is an E3 ligase ligand-linker conjugate, and incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-NH-C4-NH2 TFA is used in PROTAC BRD2/BRD4 degrader-1 (HY-130612). PROTAC BRD2/BRD4 degrader-1 is a potent and selective BET protein BRD4 and BRD2 degrader.
  • HY-136006A
    (S,R,S)-AHPC-C6-NH2 hydrochloride

    VH032-C6-NH2 hydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer Inflammation/Immunology
    (S,R,S)-AHPC-C6-NH2 hydrochloride (VH032-C6-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 hydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1.
  • HY-133487
    (S,R,S)-AHPC-C8-NH2 dihydrochloride

    VH032-C8-NH2 dihydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer Inflammation/Immunology
    (S,R,S)-AHPC-C8-NH2 dihydrochloride (VH032-C8-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1.
  • HY-130711A
    (S,R,S)-AHPC-C3-NH2 TFA

    VH032-C3-NH2 TFA

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C3-NH2 TFA (VH032-C3-NH2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader.
  • HY-130711
    (S,R,S)-AHPC-C3-NH2

    VH032-C3-NH2

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader.
  • HY-133487A
    (S,R,S)-AHPC-C8-NH2 hydrochloride

    VH032-C8-NH2 hydrochloride

    		 E3 Ligase Ligand-Linker Conjugate Cancer Inflammation/Immunology
    (S,R,S)-AHPC-C8-NH2 hydrochloride (VH032-C8-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 hydrochloride is XF038-164A, example 8, extracted from patent WO2019173516A1.
  • HY-44103
    Desmethyl-QCA276

    PROTAC BRD4-binding moiety 4

    		 Ligand for Target Protein for PROTAC Cancer
    Desmethyl-QCA276, the QCA276-based moiety, binds to cereblon ligand via a linker to form PROTAC to degrade BET. QCA276 is a BET inhibitor with an IC50 of 10 nM, and with a Ki of 2.3 nM.
  • HY-22024
    5-Hydroxyflavone

    		Others Cancer
    5-Hydroxyflavone, a flavonoid ligand, shows no cytotoxic activity against MCF-7, FaDU, MDA-MB-435S, U87, RPE-1, and HEK293 cells.
  • HY-128838
    PROTAC ERRα Degrader-1

    		PROTAC Estrogen Receptor/ERR Cancer
    PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an PROTAC estrogen-related receptor alpha (ERRa) degrader.
  • HY-P1166
    UFP-803

    		Urotensin Receptor Cardiovascular Disease
    UFP-803 is a potent urotensin-II receptor (UT) ligand. UFP-803 has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the UT system in physiology and pathology.
  • HY-101310
    SYM 2081

    		iGluR Neurological Disease
    SYM 2081 is a high-affinity ligand and potent, selective agonist of kainate receptors, inhibits [ 3H]-kainate binding with an IC50 of 35 nM, almost 3000- and 200-fold selectivity for kainate receptors over AMPA and NMDA receptors respectively.
  • HY-N0499
    Cyanidin Chloride

    IdB 1027

    		 Others Cancer
    Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties. Cyanidin Chloride (IdB 1027) inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression.
  • HY-B2087S
    Glycerol phenylbutyrate-D15

    HPN-100-D15

    		 Sigma Receptor Cardiovascular Disease
    Glycerol phenylbutyrate-D15 is a deuterium labeled Glycerol phenylbutyrate. Glycerol phenylbutyrate is a sigma-2 (σ2) receptor ligand, with a pKi of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug.
  • HY-135250B
    Thalidomide-O-C6-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12 F36V and BET.
  • HY-114872
    SLF

    		Ligand for Target Protein for PROTAC FKBP Cancer
    SLF is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for FKBP51 and an IC50 of 0.22 μM for FKBP12. SLF can be used in the synthesis of PROTAC.
  • HY-10232
    THIP

    Gaboxadol

    		 GABA Receptor Neurological Disease
    THIP (Gaboxadol) is a selective δ-aminobutyric acid type A receptor (δ-GABAAR) agonist, functionally selective GABAAR ligand, exhibits agonism at α4β1δ, α4β3δ and weak antagonism at αβγ and α4β2δ GABAARs.
  • HY-131232
    Desmorpholinyl Navitoclax-NH-Me

    Desmorpholinyl ABT-263-NH-Me

    		 Bcl-2 Family Ligand for Target Protein for PROTAC Cancer
    Desmorpholinyl Navitoclax-NH-Me is a Bcl-xL inhibitor. Desmorpholinyl Navitoclax-NH-Me and a CRBN ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC BCL-XL degrader XZ739 (HY-133557).
  • HY-108372
    Boc-C5-O-C5-O-C6-Cl

    PROTAC Linker 2

    		 PROTAC Linker Cancer
    Boc-C5-O-C5-O-C6-Cl (PROTAC Linker 2) is a PROTAC linker utilized to connect the respective tyrosine kinase inhibitor (TKI) to the E3 recruiting ligand.
  • HY-B2087S1
    Glycerol phenylbutyrate-D5

    HPN-100-D5

    		 Sigma Receptor Cardiovascular Disease
    Glycerol phenylbutyrate-D5 is a deuterium labeled Glycerol phenylbutyrate. Glycerol phenylbutyrate is a sigma-2 (σ2) receptor ligand, with a pKi of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug.
  • HY-135250
    Thalidomide-O-C6-NH2

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12 F36V and BET.
  • HY-112603
    AP5

    		GPR40 Metabolic Disease
    AP5 exhibits potent and selective agonism for the GPR40 receptor with positive allosteric modulation of endogenous ligands (AgoPAM). AP5 demonstrates a rat hIP1 EC50 of 0.49±0.28 nM against the GPR40 receptor.
  • HY-N2078
    Yamogenin

    Neodiosgenin

    		 LXR Metabolic Disease
    Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin (Neodiosgenin) antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin (Neodiosgenin) inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes.
  • HY-124619
    GPI-1046

    		FKBP HIV Infection Neurological Disease
    GPI-1046 is a immunophilin ligand without antibiotic action and attenuates ethanol intake in part through the upregulation of glutamate transporter 1 (GLT1) in PFC and NAc-core. GPI-1046 is an analog of FK506, which is an immunophilin ligand that has been shown neuroprotective effects in neurodegenerative disease models. GPI-1046 readily crosses the blood-brain barrier and promotes the regeneration of dopamine (DA) cells in the CNS in association with functional recovery in rodent models. GPI-1046 improves HIV-associated injury of peripheral nerves.
  • HY-130816
    (S,R,S)-AHPC-O-Ph-PEG1-NH2

    VH032-O-Ph-PEG1-NH2

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-O-Ph-PEG1-NH2 (VH032-O-Ph-PEG1-NH2) is E3 ligase ligand-linker conjugate and incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-O-Ph-PEG1-NH2 is used in PROTAC EED degrader-1 (HY-130614). PROTAC EED degrader-1 is a PROTAC targeting EED with a pKD of 9.02.
  • HY-130709
    PROTAC CDK2/9 Degrader-1

    		PROTAC CDK Cancer
    PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC50=62 nM) and CDK9 (DC50=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC50=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with CRBN ligand.
  • HY-17537
    APY29

    		IRE1 Cancer
    APY29, an ATP-competitive inhibitor, is an allosteric modulator of IRE1α which inhibits IRE1α autophosphorylation by binding to the ATP-binding pocket with IC50 of 280 nM. APY29 acts as a ligand that allosterically activates IRE1α adjacent RNase domain.
  • HY-135034
    UMB68 sodium

    		Others Neurological Disease
    UMB68 sodium is a selective GHB receptor ligand. UMB68 sodium displaces [ 3H]NCS-382 with an IC50 of 38 nM in rat cerebrocortical membranes. UMB68 sodium has no significant affinity at GABAB receptors, cannot be metabolized to GABA-active compounds.
  • HY-128605
    PD-1-IN-22

    		PD-1/PD-L1 Cancer
    PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC50 of 92.3 nM.
  • HY-135250A
    Thalidomide-O-C6-NH2 TFA

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12 F36V and BET.
  • HY-129363
    AP1867-3-(aminoethoxy)

    		Ligand for Target Protein for PROTAC FKBP Cancer
    AP1867-3-(aminoethoxy), the AP1867 based moiety, is a synthetic ligand for FKBP. AP1867-3-(aminoethoxy) can be used in the synthesis of PROTAC FKBP12 F36V degrader.
  • HY-P1166A
    UFP-803 TFA

    		Urotensin Receptor Cardiovascular Disease
    UFP-803 TFA is a potent urotensin-II receptor (UT) ligand. UFP-803 TFA has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the UT system in physiology and pathology.
  • HY-120210
    XY018

    		ROR Cancer Inflammation/Immunology
    XY018 is a potent ROR-γ-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC50, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD).
  • HY-B2078A
    Eprazinone dihydrochloride

    		Neurokinin Receptor Inflammation/Immunology
    Eprazinone dihydrochloride is a gent with mucolytic, secretolytic, antitussive, and bronchial antispasmodic properties. Eprazinone dihydrochloride is a neurokinin 1 receptor (NK1R) ligand. Eprazinone dihydrochloride has the potential for chronic bronchitis treatment that improved pulmonary function and arterial partial pressure of oxygen.
  • HY-44432
    Navitoclax-piperazine

    ABT-263-piperazine

    		 Bcl-2 Family Ligand for Target Protein for PROTAC Cancer
    Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604).
  • HY-136163
    (S,R,S)-AHPC-C2-NH2 dihydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C2-NH2 dihydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-OH can be used in the synthesis of a series of PROTACs.
  • HY-128842
    PROTAC MDM2 Degrader-3

    		PROTAC MDM-2/p53 E1/E2/E3 Enzyme Cancer
    PROTAC MDM2 Degrader-3 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-3 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.
  • HY-128843
    PROTAC MDM2 Degrader-4

    		PROTAC MDM-2/p53 E1/E2/E3 Enzyme Cancer
    PROTAC MDM2 Degrader-4 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-4 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.
  • HY-108635
    C16-PAF

    PAF (C16)

    		 Endogenous Metabolite
    C16-PAF is an endogenous platelet-activating factor (PAF) and ligand for PAF receptors. C16-PAF is produced by inflammatory cells and a potent chemoattractant for polymorphonuclear neutrophils. C16-PAF induces increased vascular permeability.
  • HY-128840
    PROTAC MDM2 Degrader-1

    		PROTAC MDM-2/p53 E1/E2/E3 Enzyme Cancer
    PROTAC MDM2 Degrader-1 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-1 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.
  • HY-128841
    PROTAC MDM2 Degrader-2

    		PROTAC MDM-2/p53 E1/E2/E3 Enzyme Cancer
    PROTAC MDM2 Degrader-2 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-2 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.
  • HY-122872
    MKK7-COV-9

    		p38 MAPK Cancer
    MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC50 of 4.98 μM.
  • HY-130619
    Boc-C1-PEG3-C4-OBn

    		PROTAC Linker Cancer
    Boc-C1-PEG3-C4-OBn (PROTAC Linker 15) is a PROTAC linker, which refers to the PEG composition. Boc-C1-PEG3-C4-OBn can be used in the synthesis of a series of PROTACs, such as PROTAC SGK3 degrader-1 (HY-125878). PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-133234
    BMVC-8C3O

    		G-quadruplex Others
    BMVC-8C3O is a DNA G-quadruplexe (G4) ligand which can induce topological conversion of non-parallel to parallel forms in human telomeric DNA G4s.
  • HY-P9920
    Ramucirumab

    		VEGFR Cancer
    Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D.
  • HY-14422
    SR1078

    		ROR Cancer
    SR1078 is a selective agonist of retinoic acid receptor-related orphan receptor α/γ (RORα/RORγ). SR1078 directly binds to the ligand binding domain of RORα and RORγ and increases the transcriptional activity of these receptors, leading to stimulation of RORα/γ target gene transcription.
  • HY-W040270
    Amino-PEG10-amine

    		PROTAC Linker Cancer
    Amino-PEG10-amine, a PEG-based PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.
  • HY-13956S
    Pioglitazone D4

    U 72107 D4

    		 PPAR Ferroptosis Cancer Metabolic Disease
    Pioglitazone D4 (U 72107 D4) is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
  • HY-110318
    VUF11207 fumarate

    		CXCR Cancer
    VUF11207 fumarate (Compound 29) is a CXCR7 agonist and a high-potency CXCR7 (pKi of 8.1) ligand that induces recruitment of β-arrestin2 (pEC50 of 8.8) and subsequent internalization (pEC50 of 7.9) of CXCR7.
  • HY-P1297
    CRF(6-33)(human)

    		CRFR Neurological Disease
    CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect.
  • HY-107443
    I-BET762 carboxylic acid

    Molibresib carboxylic acid; GSK525762A carboxylic acid; PROTAC BRD4-binding moiety 2

    		 Ligand for Target Protein for PROTAC Epigenetic Reader Domain Cancer
    I-BET762 carboxylic acid (Molibresib carboxylic acid) is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET. I-BET762 carboxylic acid (Molibresib carboxylic acid) is a BRD4 inhibitor with a pIC50 of 5.1.
  • HY-P1219
    Jingzhaotoxin-III

    		Sodium Channel Neurological Disease
    Jingzhaotoxin-III is a potent and selective blocker of Nav1.5 channels, with an IC50 of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype.
  • HY-N0368
    Linalool

    		iGluR Apoptosis Endogenous Metabolite Cancer Cardiovascular Disease
    Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of Nmethyl d-aspartate (NMDA) receptor, with anti-tumor, anti-cardiotoxicity activity.Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome.
  • HY-120879
    PF2562

    		Dopamine Receptor Neurological Disease
    PF2562 (Example 6), a dopamine D1 ligand, ascts as a dopamine D1 agonist or partial agonist. PF2562 binds to human D1 receptor with a Ki of 113 nM. PF2562 exhibits activity against human D1 cAMP with an EC50 of 568 nM in HTRF assay.
  • HY-136160
    Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride can be used to design the PROTACs.
  • HY-130411
    Amino-PEG11-amine

    		PROTAC Linker Cancer
    Amino-PEG11-amine, a PEG-based (12 units) PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.
  • HY-130835
    FKBP12 PROTAC RC32

    RC32

    		 PROTAC FKBP Cancer
    FKBP12 PROTAC RC32 (RC32) is a potent FKBP12 degrader based on PROTAC technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an E3 ubiquitin ligase (Pomalidomide; HY-10984).
  • HY-N0443
    N-Methylcytisine

    Caulophylline

    		 nAChR Inflammation/Immunology
    N-Methylcytisine (Caulophylline), a tricyclic quinolizidine alkaloid, exerts hypoglycaemic, analgesic and anti-inflammatory activities. N-methylcytisine is a selective ligand of nicotinic receptors of acetylcholine in the central nervous system and has a high affinity (Kd = 50 nM) to nicotinic acetylcholine receptors (nAChR) from squid optical ganglia.
  • HY-15615A
    TIC10

    ONC-201

    		 TNF Receptor Apoptosis Cancer
    TIC10 is a potent, orally active, and stable tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) inducer which acts by inhibiting Akt and ERK, consequently activating Foxo3a and significantly inducing cell surface TRAIL. TIC10 can cross the blood-brain barrier.
  • HY-P1846
    Jagged-1 (188-204)

    		Notch Cancer
    Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.
  • HY-P1219A
    Jingzhaotoxin-III TFA

    		Sodium Channel Neurological Disease
    Jingzhaotoxin-III TFA is a potent and selective blocker of Nav1.5 channels, with an IC50 of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III TFA can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype.
  • HY-P1740
    RGD peptide (GRGDNP)

    		Integrin Apoptosis Inflammation/Immunology
    RGD peptide (GRGDNP) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation. RGD peptide (GRGDNP) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.
  • HY-130842
    β-Naphthoflavone-CH2-Br

    β-NF-CH2-Br

    		 Ligand for E3 Ligase Cancer
    β-Naphthoflavone-CH2-Br (β-NF-CH2-Br) is an arylhydrocarbon receptor (AhR) ligand. β-Naphthoflavone-CH2-Br can be used to synthesize the PROTAC β-NF-JQ1(HY-130256).
  • HY-136281
    DuP 734

    		Sigma Receptor Neurological Disease
    DuP 734 is a sigma receptor antagonist. DuP 734 is a selective and potent sigma and 5-HT2 receptor ligand with weak affinity for D2 receptors. DuP 734 may have antipsychotic activity without the liability of motor side effects typical of neuroleptics.
  • HY-136008A
    VH032-PEG1-NH2 dihydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    VH032-PEG1-NH2 hydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VH032-PEG1-NH2 hydrochloride can be used to design PROTACs.
  • HY-P1846A
    Jagged-1 (188-204) (TFA)

    		Notch Cancer
    Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.
  • HY-108512
    PD 144418

    		Sigma Receptor Neurological Disease
    PD 144418 is a highly affinity, potent and selective sigma 1 (σ1) receptor ligand (Ki values of 0.08 nM and 1377 nM for σ1 and σ2 respectively). PD 144418 devoids of any significant affinity for other receptors, ion channels and enzymes. PD 144418 shows potential antipsychotic activity.
  • HY-136406
    Bongkrekic acid

    		ATP Synthase Cancer Infection
    Bongkrekic acid is a mitochondrial toxin secreted by the bacteria Pseudomonas cocovenenans. Bongkrekic acid specific ligand for mitochondrial adenine nucleotide translocase (ANT) rather than the electron transport chain. Bongkrekic acid has to cross the mitochondrial inner membrane to produce its inhibitory effect on ADP/ATP transport.
  • HY-P1297A
    CRF(6-33)(human) TFA

    		CRFR Neurological Disease
    CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect.
  • HY-111874
    SNIPER(ABL)-039

    		SNIPER Bcr-Abl Cancer
    SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 nM. IC50s are 0.54 nM, 10 nM, 12 nM, and 50 nM for ABL, cIAP1, cIAP2, XIAP, respectively.
  • HY-43869
    Vipivotide tetraxetan Linker

    PSMA-617 Linker

    		 ADC Linker Cancer
    Vipivotide tetraxetan Linker (PSMA-617 Linker) is a nonclaevable peptide linker for synthesis of Vipivotide tetraxetan (PSMA-617). Vipivotide tetraxetan (PSMA-617) is a ligand used to synthesize 177Lu-PSMA-617, which is a radioactive molecule for the treatment of prostate cancer.
  • HY-P1022
    Kisspeptin-54(human)

    Metastin(human)

    		 GNRH Receptor Cancer Endocrinology
    Kisspeptin-54(human) (Metastin(human)) is an endogenous ligand for kisspeptin receptor (KISS1, GPR54). Kisspeptin-54(human) binds to rat and human GPR54 receptors with Ki values of 1.81 nM and 1.45 nM, respectively. Kisspeptin-54(human) hinders tumor metastasis and stimulates gonadotropin secretion.
  • HY-P1306
    Obestatin(rat)

    		GHSR Inflammation/Immunology Cardiovascular Disease
    Obestatin(rat), encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) has anti-inflammatory, anti-myocardial infarction and antioxidant activities.
  • HY-P1740A
    RGD peptide (GRGDNP) (TFA)

    		Integrin Apoptosis Inflammation/Immunology Cancer
    RGD peptide (GRGDNP) (TFA) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation. RGD peptide (GRGDNP) (TFA) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.
  • HY-130683
    Lenalidomide-propargyl-C2-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Lenalidomide-propargyl-C2-NH2 hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Lenalidomide-propargyl-C2-NH2 hydrochloride can be used to design the PROTAC MD-224 (HY-114312).
  • HY-130638
    (S,R,S)-AHPC-O-Ph-PEG1-NH-Boc

    VH032-O-Ph-PEG1-NH-Boc

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-O-Ph-PEG1-NH-Boc (VH032-O-Ph-PEG1-NH-Boc) is a synthesized E3 ligase ligand-linker conjugate which is used for the EED-targeted PROTAC.
  • HY-111848
    PROTAC AR Degrader-4

    		SNIPER PROTAC Androgen Receptor Cancer
    PROTAC AR Degrader-4 comprises a cIAP1 ligand binding group, a linker and an androgen receptor (AR) binding group. PROTAC AR Degrader-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs).
  • HY-111905
    BRD7-IN-1

    		Epigenetic Reader Domain Cancer
    BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC50s of 4.5 and 1.8 nM, respectively).
  • HY-P1525
    Melanin Concentrating Hormone, salmon

    MCH (salmon)

    		 MCHR1 (GPR24) Metabolic Disease Neurological Disease Cardiovascular Disease Endocrinology
    Melanin Concentrating Hormone, salmon is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.
  • HY-118482
    Sauristolactam

    Saurolactam

    		 Others Neurological Disease
    Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus chinensis, has significant neuroprotective activity against glutamate-induced toxicity in primary cultured rat cortical cells. Sauristolactam also inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and has the potential to inhibit osteoclast differentiation.
  • HY-123921
    Gefitinib-based PROTAC 3

    		PROTAC EGFR Cancer
    Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively.
  • HY-108512A
    PD 144418 oxalate

    		Sigma Receptor Neurological Disease
    PD 144418 oxalate is a highly affinity, potent and selective sigma 1 (σ1) receptor ligand (Ki values of 0.08 nM and 1377 nM for σ1 and σ2 respectively). PD 144418 oxalate devoids of any significant affinity for other receptors, ion channels and enzymes. PD 144418 oxalate shows potential antipsychotic activity.
  • HY-128838A
    (rel)-PROTAC ERRα Degrader-1

    		Others Others
    (rel)-PROTAC ERRα Degrader-1 is a relative configuration of PROTAC ERRα Degrader-1. PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an estrogen-related receptor alpha (ERRa) degrader.
  • HY-108006
    Mirogabalin besylate

    DS 5565 besylate

    		 Calcium Channel Neurological Disease
    Mirogabalin besylate is a selective and orally available ligand for the α2δ subunit of voltage-gated calcium channels, with Kds of 13.5 nM, 22.7 nM, 27 nM, and 47.6 nM for human α2δ-1, human α2δ-2, rat α2δ-1, and rat α2δ-2, respectively.
  • HY-111905A
    BRD7-IN-1 free base

    		Epigenetic Reader Domain Cancer
    BRD7-IN-1 free base, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC50s of 4.5 and 1.8 nM, respectively).
  • HY-130256
    β-NF-JQ1

    		PROTAC Epigenetic Reader Domain Cancer
    β-NF-JQ1 is a PROTAC that recruits AhR E3 ligase to target proteins. β-NF-JQ1 is directed against bromodomain-containing (BRD) proteins using β-NF as an AhR ligand, induces the interaction of AhR and BRD proteins, and displays effective anticancer activity that correlated with protein knockdown activity.
  • HY-P1039
    R18

    PHCVPRDLSWLDLEANMCLP

    		 Others Cancer
    R18 is a peptide antagonists of 14-3-3, with a KD of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1.
  • HY-107452
    SLF-amido-C2-COOH

    PROTAC FKBP12-binding moiety 1

    		 Ligand for Target Protein for PROTAC FKBP Cancer
    SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) is a synthetic ligand for FKBP (SLF). SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) can be used in the synthesis of PROTACs.
  • HY-114407
    TD-428

    		PROTAC Epigenetic Reader Domain Cancer
    TD-428 is a highly specific BRD4 degrader with a DC50 of 0.32 nM. TD-428 is a BET PROTAC, which comprises TD-106 (a CRBN ligand) linked to JQ1 (a BET inhibitor). TD-428 efficiently induce BET protein degradation.
  • HY-P1306A
    Obestatin(rat) TFA

    		GHSR Inflammation/Immunology Cardiovascular Disease
    Obestatin(rat) TFA, encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) TFA suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) TFA has anti-inflammatory, anti-myocardial infarction and antioxidant activities.
  • HY-112210
    Shield-1

    		FKBP Others
    Shield-1 is a specific, cell-permeant and high-affinity ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to mutated FKBP (mtFKBP), allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize the entire fusion protein.
  • HY-107453
    SirReal1-O-propargyl

    PROTAC Sirt2-binding moiety 1

    		 Ligand for Target Protein for PROTAC Cancer
    SirReal1-O-propargyl is a selective and highly potent Sirtuin 2 (Sirt2) inhibitor, with an IC50 of 2.4 μM. SirReal1-O-propargyl, the SirReal1-based moiety, binds to the cereblon ligand via a linker to form PROTAC to degrade Sirt2.
  • HY-114169
    WRG-28

    		Discoidin Domain Receptor Cancer
    WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor with an IC50 of 230 nM. WRG-28 uniquely inhibits receptor-ligand interactions via allosteric modulation of the receptor. WRG-28 inhibits tumor invasion and migration, as well as tumor-supporting roles of the stroma, and inhibits metastatic breast tumor cell colonization in the lungs by targeting DDR2.
  • HY-P1525A
    Melanin Concentrating Hormone, salmon TFA

    MCH (salmon) (TFA)

    		 MCHR1 (GPR24) Metabolic Disease Neurological Disease Cardiovascular Disease Endocrinology
    Melanin Concentrating Hormone, salmon TFA (MCH (salmon) TFA) is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.
  • HY-P1022A
    Kisspeptin-54(human) TFA

    Metastin(human) TFA

    		 GNRH Receptor Cancer Endocrinology
    Kisspeptin-54(human) TFA (Metastin(human) TFA) is an endogenous ligand for kisspeptin receptor (KISS1, GPR54). Kisspeptin-54(human) TFA binds to rat and human GPR54 receptors with Ki values of 1.81 nM and 1.45 nM, respectively. Kisspeptin-54(human) TFA hinders tumor metastasis and stimulates gonadotropin secretion.
  • HY-130682
    Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase and a linker. Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride can be used to design the PROTAC MD-224 (HY-114312).
  • HY-135881
    OMDM-5

    		TRP Channel Endogenous Metabolite Neurological Disease
    OMDM-5 is a selective inhibitor of anandamide cellular uptake (ACU), with a Ki of 4.8 μM. OMDM-5 is also a potent vanilloid receptor type 1 (VR1, TRPV1) agonist, with an EC50 of 75 nM, and shows weakly active as cannabinoid receptor type 1 (CB1) ligand (Ki=4.9 μM).
  • HY-122054
    BPK-29

    		Others Cancer
    BPK-29 is a specific ligand that disrupts the atypical orphan nuclear receptor NR0B1-protein (such RBM45 and SNW1) interactions by covalently modifying C274. BPK-29 impairs the anchorage-independent growth of KEAP1-mutant cancer cells.
  • HY-122054A
    BPK-29 hydrochloride

    		Others Cancer
    BPK-29 hydrochloride is a specific ligand that disrupts the atypical orphan nuclear receptor NR0B1-protein (such RBM45 and SNW1) interactions by covalently modifying C274. BPK-29 hydrochloride impairs the anchorage-independent growth of KEAP1-mutant cancer cells.
  • HY-133139
    Lenalidomide-PEG1-azide

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Lenalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Lenalidomide-PEG1-azide incorporates the Lenalidomide based cereblon ligand and a linker. Lenalidomide-PEG1-azide can be used to design a PROTAC BRD4 Degrader-2 (HY-133136).
  • HY-130654
    (S,R,S)-AHPC-C2-PEG4-N3

    VH032-C2-PEG4-N3

    		 E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. (S,R,S)-AHPC-C2-PEG4-N3 can be used in the synthesis of vRucaparib-TP4 (HY-130647). vRucaparib-TP4 a highly potent PARP1 degrader with a half-maximal degrading concentration (DC50) of 82 nM.
  • HY-130642
    (S,R,S)-AHPC-Me-C10-Br

    		E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-Me-C10-Br is a synthesized E3 ligase ligand-linker conjugate. (S,R,S)-AHPC-Me-C10-Br incorporates a VHL E3 ligase linker and MS432 based on the MEK1/2 inhibitor PD0325901.
  • HY-16781
    Grapiprant

    CJ-023423; RQ-00000007; AAT-007

    		 Prostaglandin Receptor Metabolic Disease Endocrinology
    Grapiprant (CJ-023423) is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2). Grapiprant displaces [ 3H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor with IC50 value of 35 nM and Ki value of 24 nM. Grapiprant has the potential for osteoarthritic pain and inflammation treatment[3] .
  • HY-W020790
    Sialyl-Lewis X

    sLeX

    		 Others Inflammation/Immunology
    Sialyl-Lewis X (sLeX) is a sialylated fucosylated tetrasaccharide, an endogenous antigen. Sialyl-Lewis X is a high-affinity ligand for selectins (E-, P-, and L-selectin). Sialyl-Lewis X binds to ELAM-1 and CD62 and has the ability to inhibits CD62-mediated neutrophil recruitment to sites of inflammation.
  • HY-129603
    SI-109

    		STAT Ligand for Target Protein for PROTAC Cancer
    SI-109 is a potent STAT3 SH2 domain inhibitor (Ki=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC50=3 μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader SD-36.
  • HY-130713
    Thalidomide-C2-amido-C2-COOH

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Thalidomide-C2-amido-C2-COOH incorporates a CRBN ligand for the E3 ubiquitin ligase, and a linker. Thalidomide-C2-amido-C2-COOH can be used to design PROTAC CDK2/9 Degrader-1 (HY-130709).
  • HY-107676
    SIB-1553A

    		nAChR Neurological Disease
    SIB-1553A is an orally bioavailable nicotinic acetylcholine receptors (nAChRs) agonist, with selectivity for β4 subunit-containing nAChRs. SIB-1553A is also a selective neuronal nAChR ligand. SIB-1553A is a cognitive enhancer, and has therapeutic potential for the symptomatic treatment of Alzheimer’s disease and other cognitive disorders.
  • HY-133138
    Pomalidomide-PEG1-azide

    		E3 Ligase Ligand-Linker Conjugate Cancer
    Pomalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-PEG1-azide can be used to design a PROTAC BRD4 Degrader-1 (HY-133131).
  • HY-131188
    PROTAC Bcl-xL degrader-1

    		PROTAC Bcl-2 Family Cancer
    PROTAC Bcl-xL degrader-1 is a PROTAC that comprises a Bcl-xL ligand binding group, a linker and an IAP E3 ligases binding group. PROTAC Bcl-xL degrader-1 is a potent Bcl-xL degrader, and shows toxicity for human platelets and MyLa 1929 cells with IC50 values of 62 nM and 8.5 μM, respectively.
  • HY-N2025
    Oroxin A

    		PARP Glucosidase Metabolic Disease
    Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE), activates peroxisome proliferator-activated receptor γ (PPARγ) by docking into the PPARγ protein ligand-binding domain. Oroxin A exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity. Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence.
  • HY-15523A
    Braco-19 trihydrochloride

    		DNA/RNA Synthesis CMV Cancer Infection
    Braco-19 trihydrochloride is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor.
  • HY-13912
    IWP-2

    		Wnt Casein Kinase Cancer
    IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and thus preventing a crucial Wnt ligand palmitoylation. IWP-2 is also an ATP-competitive CK1δ inhibitor with an IC50 of 40 nM for the gatekeeper mutant M82FCK1δ.
  • HY-122607
    DPA-714

    		Others Cancer Inflammation/Immunology
    DPA-714 is a high affinity translocator protein (TSPO) ligand (Ki=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. [18F]DPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model.
  • HY-15523
    Braco-19

    		CMV DNA/RNA Synthesis Cancer
    Braco-19 is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor.
  • HY-110358
    QAQ dichloride

    		Sodium Channel Inflammation/Immunology
    QAQ dichloride, a photoswitchable voltage-gated Nav and Kv channels blocker, blocks channels in its trans form (of the azobenzene photoswitch), but not in its cis form. QAQ dichloride is membrane-impermeant and only infiltrates pain-sensing neurons that express endogenous import channels. QAQ dichloride acts as a light-sensitive analgesic and can be used for studying of signaling mechanisms in acute and chronic pain.
  • HY-111846
    PROTAC ERα Degrader-2

    		SNIPER PROTAC Estrogen Receptor/ERR Cancer
    PROTAC ERα Degrader-2 comprises a cIAP1 ligand binding group, a linker and an estrogen receptor α (ERα) binding group. PROTAC ERα Degrader-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs).
  • HY-10019
    Varenicline

    CP 526555

    		 nAChR Neurological Disease
    Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively. Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment.
  • HY-111546
    BI-3663

    		PROTAC FAK Cancer
    BI-3663 is a highly selective PTK2/FAK PROTAC, with cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC50 of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 (HY-124625) linked to Pomalidomide (HY-10984) with a linker. Anti-cancer activity.
  • HY-110287
    Apcin

    		APC Cancer
    Apcin, a ligand of Cdc20, is a potent and competitive anaphase-promoting complex/cyclosome (APC/C(Cdc20)) E3 ligase activity inhibitor. Apcin competitively inhibits APC/C-dependent ubiquitylation by binding to Cdc20 and preventing substrate recognition. Apcin occupes the D-box-binding pocket on the side face of the WD40-domain and can prolong mitosis.
  • HY-P2036
    FSL-1

    		Toll-like Receptor (TLR) Antibiotic Infection
    FSL-1 is a TLR2/6 agonist (also a putative TLR10 ligand). FSL-1 activates NF-κB. FSL-1 induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. FSL-1 synergizes with IFNγ to induce CXCL10 release from melanoma cells.
  • HY-100277
    Mifobate

    SR-202

    		 PPAR Metabolic Disease
    Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects.
  • HY-10046
    Plerixafor

    AMD 3100; JM3100; SID791

    		 CXCR HIV Virus Protease Cancer Infection Endocrinology Inflammation/Immunology
    Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM.
  • HY-12397
    ZK159222

    		VD/VDR Endocrinology
    ZK159222, a 25-carboxylic ester analogue of 1α,25-(OH)2D3, is a potent 1α,25-(OH)2D3 receptor (VDR) antagonist. The mechanism of ZK159222 antagonistic action is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators. ZK159222 has a partial agonistic character.
  • HY-12028
    PD98059

    		MEK Aryl Hydrocarbon Receptor Autophagy Cancer
    PD98059 is a potent and selective MEK inhibitor with an IC50 of 5 µM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC50 of 2-7 µM) and MEK2 (IC50 of 50 µM) by upstream kinases. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC50 of 4 μM) and AHR transformation (IC50 of 1 μM). PD98059 also inhibits autophagy.
  • HY-N2453
    Convallatoxin

    		PPAR NF-κB P-glycoprotein Cancer Inflammation/Immunology
    Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties.
  • HY-117727
    Leriglitazone

    Hydroxypioglitazone

    		 PPAR Metabolic Disease
    Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with Ki of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC50 of 680 nM.
  • HY-P1204
    [Ala17]-MCH

    		MCHR1 (GPR24) Metabolic Disease
    [Ala17]-MCH, a MCH analogue (HY-P1525A), is a selective ligand for MCHR1 (Ki=0.16 nM) over MCHR2 (Ki=34 nM). [Eu 3+ chelate-labeled [Ala17]-MCH shows high affnity for MCHR1 (Kd=0.37 nM) while has little demonstrable binding affnity for MCHR2.
  • HY-P1204A
    [Ala17]-MCH TFA

    		MCHR1 (GPR24) Metabolic Disease
    [Ala17]-MCH TFA, a MCH analogue (HY-P1525A), is a selective ligand for MCHR1 (Ki=0.16 nM) over MCHR2 (Ki=34 nM). [Eu 3+ chelate-labeled [Ala17]-MCH shows high affnity for MCHR1 (Kd=0.37 nM) while has little demonstrable binding affnity for MCHR2.
  • HY-100848
    TX1-85-1

    		EGFR Cancer
    TX1-85-1 is an irreversible Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.
  • HY-125877
    PROTAC Mcl1 degrader-1

    		PROTAC Bcl-2 Family Cancer
    PROTAC Mcl1 degrader-1 (compound C3), a proteolysis targeting chimera (PROTAC), is a potently and selectively Mcl-1 inhibitor with an IC50 of 0.78 μM. PROTAC Mcl1 degrader-1 induces the ubiquitination and proteasomal degradation of Mcl-1 by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1 inhibitor S1-6 with μM-range affinity.
  • HY-125876
    PROTAC Bcl2 degrader-1

    		PROTAC Bcl-2 Family Cancer
    PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC, which potently and selectively induces the degradation of Bcl-2 (IC50, 4.94 μM; DC50, 3.0 μM) and Mcl-1 (IC50, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1.
  • HY-P2036A
    FSL-1 TFA

    		Toll-like Receptor (TLR) Antibiotic Infection
    FSL-1 TFA is a TLR2/6 agonist (also a putative TLR10 ligand). FSL-1 TFA activates NF-κB. FSL-1 TFA induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. FSL-1 TFA synergizes with IFNγ to induce CXCL10 release from melanoma cells.
  • HY-126252
    A-9758

    		ROR Interleukin Related Inflammation/Immunology
    A-9758 is a RORγ ligand and a potent, selective RORγt inverse agonist (IC50=5 nM), and exhibits robust potency against IL-17A release. A-9758 is effective in suppressing both Th17 differentiation and Th17 effector function. A-9758 significantly attenuates IL-23 driven psoriasiform dermatitis and is effective in blocking skin and joint inflammation.
  • HY-112495
    VH032-PEG5-C6-Cl

    HaloPROTAC 2

    		 PROTAC Cancer
    VH032-PEG5-C6-Cl (HaloPROTAC 2) is a small molecule HaloPROTAC that incorporates the VH032 based VHL ligand and 5-unit PEG linker. VH032-PEG5-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
  • HY-13001
    Quizartinib

    AC220

    		 FLT3 Ligand for Target Protein for PROTAC Apoptosis Autophagy Cancer
    Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a Kd of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC50s of 4.2 and 1.1 nM, respectively. Quizartinib can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib induces apoptosis.
  • HY-129610
    KB02-SLF

    		PROTAC FKBP Cancer
    KB02-SLF is a PROTAC-based nuclear FKBP12 degrader (molecular glue). KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF.
  • HY-130815
    MAK683-CH2CH2COOH

    		Histone Methyltransferase Ligand for Target Protein for PROTAC Cancer
    MAK683-CH2CH2COOH binds to EED (embryonic ectoderm development protein). MAK683-CH2CH2COOH and a VHL ligand for the E3 ubiquitin ligase have been used to design PROTAC EED degrader-1 (HY-130614) and PROTAC EED degrader-2 (HY-130615).
  • HY-130983
    N-piperidine Ibrutinib hydrochloride

    		Btk Ligand for Target Protein for PROTAC Cancer
    N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor with IC50s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively. N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620 (HY-133137). SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM.
  • HY-123919
    TL13-112

    		PROTAC ALK Cancer
    TL13-112 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC50 value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A, FER, PTK2 and RPS6KA1 with IC50 values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib (HY-15656) and the cereblon ligand of Pomalidomide (HY-10984).
  • HY-116624
    MAZ51

    		VEGFR Apoptosis Cancer
    MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity.
  • HY-110155
    LM11A-31 dihydrochloride

    		Others Neurological Disease
    LM11A-31 dihydrochloride, a non-peptide p75 NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 dihydrochloride is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. M11A-31 dihydrochloride reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression.
  • HY-110155A
    (Rac)-LM11A-31 dihydrochloride

    		Others Neurological Disease
    (Rac)-LM11A-31 dihydrochloride is an isomer of LM11A-31 dihydrochloride. LM11A-31 dihydrochloride, a non-peptide p75 NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist.
  • HY-P0172A
    ATI-2341 TFA

    		CXCR Cancer Inflammation/Immunology Endocrinology
    ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs).
  • HY-136242
    UT-34

    		Androgen Receptor Cancer Endocrinology
    UT-34 is a potent, selective and orally active second-generation pan-androgen receptor (AR) antagonist and degrader with IC50s of 211.7 nM, 262.4 nM and 215.7 nM for wild-type, F876L and W741L AR, respectively. UT-34 binds to ligand-binding domain (LBD) and function-1 (AF-1) domains and requires ubiquitin proteasome pathway to degrade the AR. UT-34 has anti-prostate cancer efficacy.
  • HY-122582
    TL13-12

    		PROTAC ALK Cancer
    TL13-12 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC50 value of 0.69 nM. TL13-12 also prompts the degradation of additional kinases including Aurora A, FER, PTK2, and RPS6KA1 with IC50 values of 13.5 nM, 5.74 nM, 18.4 nM, and 65 nM, respectively. TL13-12 is comprised of the conjugation of TAE684 (HY-10192) and the cereblon ligand of Pomalidomide (HY-10984).
  • HY-P0172
    ATI-2341

    		CXCR Inflammation/Immunology Endocrinology Cancer
    ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs).
  • HY-128359
    ACBI1

    		PROTAC Epigenetic Reader Domain Apoptosis Cancer
    ACBI1 is a potent PROTAC degrader of BAF ATPase subunits SMARCA2 and SMARCA4, also degrades the polybromo-associated BAF (PBAF) complex member PBRM1, with DC50s of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively. ACBI1 is composed of a bromodomain ligand, a linker, and the E3 ubiquitin ligase VHL. ACBI1 can induce anti-proliferative effects and apoptosis.
  • HY-117163
    FzM1.8

    		Wnt β-catenin Cancer
    FzM1.8 derives from FzM1, is an allosteric agonist of FZD4 with pEC50 of 6.4. FzM1.8 binds to FZD4 and activates the WNT/β-catenin pathway, by promoting TCF/LEF transcriptional activity in the absence of any WNT ligand. FzM1.8 binding stabilizes FZD4 with an increased affinity for heterotrimeric G protein and stimulates the release of the Gβγ subunit that in turn activates PI3K.
  • HY-103636
    PROTAC Sirt2 Degrader-1

    		Sirtuin PROTAC Cancer
    PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC, acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC50 of 0.25 μM for Sirt2, with no effect on Sirt1/Sirt3 (IC50s>100 μM).
  • HY-119109
    Laminaran

    		Others Cancer
    Laminaran is a neutral water-soluble β-1-3-glucan and a typical ligand for Dectin-1 isolated from the brown alga D. dichotoma, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.
  • HY-130422
    Tos-PEG4-t-butyl ester

    Tos-PEG4-Boc

    		 PROTAC Linker Cancer
    Tos-PEG4-t-butyl ester (Tos-PEG4-Boc) is a PROTAC linker, which refers to the PEG composition. Tos-PEG4-t-butyl ester (Tos-PEG4-Boc) can be used in the synthesis of a series of PROTACs, such as BI-3663 (HY-111546). BI-3663 is a highly selective PTK2/FAK PROTAC, with cereblon ligands to hijack E3 ligases for PTK2 degradation, and inhibits PTK2 with an IC50 of 18 nM.
  • HY-129917
    KB02-JQ1

    		PROTAC Epigenetic Reader Domain Cancer
    KB02-JQ1 is a highly selective and PROTAC-based BRD4 degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes BRD4 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. JQ1 binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-JQ1.
  • HY-130612
    PROTAC BRD2/BRD4 degrader-1

    		Epigenetic Reader Domain PROTAC Cancer
    PROTAC BRD2/BRD4 degrader-1 (compound 15) is a potent and selective BET protein BRD4 and BRD2 degrader. PROTAC BRD2/BRD4 degrader-1 rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 and BRD2 over BRD3. It effectively inhibits solid tumors with low cytotoxic effect. PROTAC BRD2/BRD4 degrader-1 is composed of the BET inhibitor, a linker, and the ligand thalidomide for cereblon (CRBN)/cullin 4A.
  • HY-129602
    SD-36

    		PROTAC STAT Apoptosis Cancer
    SD-36 is a potent and efficacious PROTAC STAT3 degrader (Kd=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC50=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of CRBN ligand Lenalidomide for E3 ubiquitin ligase.
  • HY-103241
    Ro 90-7501

    		Amyloid-β ATM/ATR Phosphatase Apoptosis Cancer Neurological Disease
    Ro 90-7501 is an amyloid β42 (Aβ42) fibril assembly inhibitor that reduces Aβ42-induced cytotoxicity (EC50 of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response. Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner. Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells.
  • HY-120874
    PF-06372865

    		GABA Receptor Neurological Disease
    PF-06372865 is an orally active, α2/α3/α5 subtype-selective GABAA positive allosteric modulator (PAM). PF-06372865 is a high affinity ligand at GABAA receptors containing α1/α2/α3/α5 subunits (Kis of 2.9 nM, 21 nM, 134 nM for α2, α1 PAM, α2 PAM, respectively), with low affinity for α4/α6 subunits. PF-06372865 has the potential for epilepsy.
  • HY-120944
    BAY-7598

    		MMP Inflammation/Immunology
    BAY-7598 is a potent, orally bioavailable, and selective MMP12 inhibitor probe with IC50s of 0.085, 0.67 and 1.1 nM for human MMP12, murine MMP12, and rat MMP12, respectively.
  • HY-P1320A
    [Nphe1]Nociceptin(1-13)NH2 TFA

    		Opioid Receptor Inflammation/Immunology
    [Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pKi=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA2=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent.
  • HY-131187
    BMS-1166-N-piperidine-COOH

    		Ligand for Target Protein for PROTAC Cancer
    BMS-1166-N-piperidine-COOH, the BMS-1166-based moiety, binds to E3 ligase ligand via a linker to form PROTAC PD-1/PD-L1 degrader-1 (HY-131183) to degrade PD-1/PD-L1. BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.
  • HY-P1320
    [Nphe1]Nociceptin(1-13)NH2

    		Opioid Receptor Inflammation/Immunology
    [Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pKi=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA2=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent.

As the situation with COVID-19 continues to unfold in every communities, MedChemExpress is responding to the uncertainty caused by this outbreak thoughtfully and cautiously. Your need for high quality reagent doesn't stop during difficult times, and neither do we. We're doing our best to keep everyone healthy and safe in the workplace while also avoiding the interruptions to our day-to-day operations. If you need to change the delivery plan for items ordered, please contact us via email [email protected]. Thank you for being a loyal MedChemExpress customer, we are here to assist you as needed.